Analysis of biogenic amines and their metabolites in brain tissue by high performance liquid chromatography with electrochemical detection. by Sasa, Suleiman Issa,
INFORMATION TO USERS
This material was produced from a microfilm copy of the original document. While 
the most advanced technological means to photograph and reproduce this document 
have been used, the quality is heavily dependent upon the quality of the originM 
submitted.
The following explanation of techniques is provided to help you understand 
markings or patterns which may appear on this reproduction.
1. The sign or "target" for pages apparently lacking from the document 
photographed is "Missing Page(s)". If it was possible to obtain the missing 
page(s) or section, they are spliced into the film along with adjacent pages. 
This may have necessitated cutting thru an image and duplicating adjacent 
pages to insure you complete continuity.
2. When an image on the film is obliterated with a large round black mark, it  
is an indication that tfie photographer suspected that the copy may have 
moved during exposure and thus cause a blurred image. You will find a  
good image of the page in the adjacent frame.
3. When a map, drawing or chart, etc., was part of the material being 
photographed the photographer followed a definite method in 
"sectioning" the material. It  is customary to begin photo#ng at the upper 
left hand comer of a large sheet and to continue photoing from left to  
right in equal sections with a small overlap. If  necessary, sectioning is 
continued again — beaming below the first row and continuing on until 
complete.
4. The majority of users indicate that the textual content is of greatest value, 
however, a somewhat higher quality reproduction could be made from 
"photographs" if essential to the understanding of tha dissertation. Silver 
prints of "photographs" may be ordered at additional charge by writing 
the Order Department, giving the catalog number, title, author and 
specific pages you wish reproduced.
5. PLEASE NOTE: Some pages may have indistinct print. Filmed as 
received.
University Microfilms international
300 North Zeeb Road
Ann Afbor. Michigan 48106 USA
St John's Road. Tyler's Green
High Wycombe. Bucks. England HP10 8HR
77-32,880
S ASA, Suleiman Issa, 1937-
ANALYSIS OF BIOGENIC AMINES AND THEIR 
METABOLITES IN BRAIN TISSUE BY HIGH PERFORMANCE LIQUID CHROMATOGRAPHY 
WITH ELECTROCHEMICAL DETECTION.
The University of Oklahoma,
Ph.D., 1977 
Chemistry, analytical
University Microfilms International, Ann Arbor. Michigan 4sio6
THE UNIVERSITY OF OKLAHOMA 
GRADUATE COLLEGE
ANALYSIS OF BIOGENIC AMINES AND THEIR 
METABOLITES IN BRAIN TISSUE BY HIGH 
PERFORMANCE LIQUID CHROMATOGRAPHY 
WITH ELECTROCHEMICAL DETECTION
A DISSERTATION 
SUBMITTED TO THE GRADUATE FACULTY 




SULEIMAN ISSA SASA 
Norman, Oklahoma 
1977
ANALYSTS OP BIOGENIC AMINES AND THEIR 
METABOLITES IN BRAIN TISSUE BY HIGH 





I wish to express my gratitude and appreciation 
to Dr. C. LeRoy Blank for guidance and support during the 
course of this research- It is impossible to adequately 
thank him for his patience, understanding, and enthusiasm.
Special thanks go to Dr. Glenn Dryhurst and Dr. 
Richard Taylor who always provided, together with Dr.
C. LeRoy Blank, the real friendly and harmonious atmosphere 
in our analytical chemistry division.
Special thanks go to Dr. Eddie Smith who, as a 
graduate student advisor, always showed a real concern 
and interest in helping graduate students. Special thanks 
also go to Dr. Arnulf Hagen, whose help with the writing 
of the dissertation was certainly more than was required, 
and to Dr. Pushkar Kaul whose valuable instructions and 
notes will always be remembered.
Special thanks go to Dr. William Stavinoha,
Dr. Arvin Modak and their group at the Health Sciences 
Center in San Antonio, Texas for providing brain parts 
and microwave facilities.
Special thanks go to Mr. Pat Cohenour for the
111
synthesis of the neurotoxins employed in this research. 
Special thanks also go to my fellow graduate students: 
Messrs. Robert Pike, David Wassil, Mike Bulawa, Jim Owens, 
Mike Cleary and Henry Marsh for their contributions of 
labor, ideas, and advice.
I wish to thank my loving wife, Nuha, and Mrs. 
Nancy Heinicke for their great help in preparing and 
typing this manuscript. Their help will always be 
remembered and appreciated.
Financial assistance in the form of a teaching 
assistantship from the Chemistry Department at the Univer­
sity of Oklahoma is acknowledged.
This work was supported in part by a Cottrell 
grant from Research Corporation and in part by Grant No. 
MH26866-01, awarded by the National Institutes of Mental 
Health, DHEW. This support is gratefully acknowledged.
I am most indebted to my parents who sacrificed 
for my education, and to my loving wife, Nuha, without 
whose patience and understanding, graduate work would 
have been impossible.
Finally, I heartily thank "Almighty Allah" from 





LIST OF ILLUSTRATIONS..........................  xi
Chapter
I. GENERAL INTRODUCTION ....................  1
Analytical Methodology Background ........ 7







Tissue Homogenizers .....................  23
Calculations ............................. 23
III. DEVELOPMENT OF BIOGENIC AMINES
LCEC ANALYSES  .....................  26
Initial Chromatographic Studies .......... 26
Optimal Chromatographic Conditions
for DA/5-HT Analysis .....................  30
Page
Investigation of Chromatographic 
Interferences in the DHBA/DA/5-HT
Separation..............................  31
Development of Optimal Chromatographic 
Separation for NE/DA and 5-HT Analysis . . .  35
Optimal Chromatographic Conditions
for NE/DA/5-HT Analysis.... ..............  43
Investigation of Chromatographic 
Interferences in NE/DHBA/DA/5-HT
Separation..............................  44
Isolation Procedure...... ... ........... 46
Optimization of the Extraction Procedure
for DA/S-HT Analysis .....................  49
Final Assay Procedure for DA and
5-HT Determination....................... 61
Optimization of the Extraction Procedure
for NE, DA, and 5-HT Analysis...........  64
Final Assay Procedure for the NE, DA,
and 5-HT Determination  .................  70
Modification of the NE/DA/5-HT Assay 
for the Analysis of Biogenic Amines
in Brain Parts........................... 70
IV. DETERMINATION OF DOPAMINE AND SEROTONIN
MOUSE BRAIN TISSUE APPLICATIONS........ 73
Whole Mouse B r a i n ....................... 78
vi
Page
Methods of Homogenization .................  78
Routine Application .......................  79
Column Stcibility............................  80
Mouse Brain P a r t s ......................... 80
Results and Discussion .....................  82
V. DETERMINATION OF NOREPINEPHRINE, DOPAMINE,
AND SEROTONIN IN MOUSE BRAIN TISSUE--
APPLICATIONS ............................  90
Whole Mouse Brains.......................  90
Daily Rhythms in Norepinephrine, Dopamine, 
and Serotonin Concentration in Mouse Brain . 90
Compeurison of the Effects of 6-Amino- 
dopamine and a-Methy1-6-aminodopamine
on the Central Nervous System...........  95
Simultaneous Estimation of Norepinephrine, 
Dopamine, and Serotonin in Seven Discrete
Areas of Mouse Brain.....................  99
Results and Discussion ..................... 100
References................................  104




3-1 Examination of Potential Interferences
in the DHBA/DA/5-HT Separation.........  32
3-2 Examination of Potential Interferences
in NE/DHBA/DA/5-HT Separation .........  45
3-3 Percent Recovery of Amines as a Function 
of Initial Shaking Time. Standard
Solutions............................  51
3-4 Percent Recovery of Amines when Extracted
in Presence of EDTA and Ascorbic Acid . . 52
3-5 Percent Recovery of Amines for Purified 
and Unpurified Butanol and Heptane
Extraction Solvents .....................  53
3-6 Resolution between Adjacent Chromatographic
Peaks as a Function of Injected Volume . . 54
3-7 Percent Recovery as a Function of Initial
Aqueous pH Value......................... 57
3-8 Percent Recovery in Presence and Absence
of Brain Tissue— DHBA/DA/5-HT Extraction . 59
3-9 Percent Recovery in Presence and Absence
of Brain Tissue— NE'/DHBA/DA/5-HT Extraction 67
viii
Table Page
3-10 Study of the Stability of the Final 
Extract of NE, DA, and 5-HT at Room 
Temperature in Presence of Brain
Tissue................................  69
3-11 Study of the Stability of the Final 
Extract of NE, DA, and 5-HT at Room 
Temperature in Absence of Brain Tissue . . 69
3-12 Solutions Added Prior to Homogenization
for Brain Parts Analyses ...............  74
3-13 Materials Used for Extraction in Brain
Parts Analyses......................... 75
3-14 Working Standards Used in Brain Parts 
Analyses..............................  76
4-1 Whole Mouse Brain Dopamine and
Serotonin Concentrations ...............  79
4-2 Effect of Homogenization Method on Whole 
Mouse Brain Determination of Dopamine
and Serotonin......................... 80
4-3 Dopamine and Serotonin Concentrations
of Mouse Brain Parts ...................  83
4-4 Dopamine and Serotonin Concentrations
in Mouse Striatum After Immobilization . . 85
4-5 Concentrations of Dopamine in Striatum 




5-1 Whole Mouse Brain Analysis-Liquid
Chromatography Method .................  91
5-2 Whole Mouse Brain Analysis-Literature
Values...........................  91
5-3 Norpinephrine, Dopamine, and Serotonin
Concentrations in Mouse Brain at Certain
Times of D a y .....................  93
5-4 Depletion of Norepinephrine, Dopamine, 
and Serotonin in Whole Mouse Brain by
6—ADA and a—Me—6—ADA . . . . . . . . . . .  98
5-5 Concentrations of Norepinephrine, Dopamine,
and Serotonin in Regions of Mouse Brain . 101
LIST OF ILLUSTRATIONS 
Figure Page
1-1 Major Metabolic Pathways for the
Synthesis and Metabolism of Serotonin. . . 3
1-2 Biosynthesis of the Catecholamines,
Norepinephrine and Dopamine ...........  5
2-1 LCEC Apparatus.........................  16
2-2 The Electrochemical Detector  ..........  19
3-1 A Typical Whole Mouse Brain Chromatogram,
Direct Brain Injection .................  38
3-2 A Whole Mouse Brain Chromatogram after
Column Deterioration Due to Direct Brain
Injections............................. 39
3-3 A Typical Chromatogram Employing the High
Pressure System.......................  41
3-4 A Chromatogram Showing the Effect of
Increasing Injection Volume on Resolution 
of Solvent, DHBA, DA, and 5-HT Peaks . . .  55
3-5 A Typical Whole Mouse Brain Chromatogram
for DA/5-HT Analysis ...................  63
3-6 A Typical ïihole Mouse Brain Chromatogram
for NE, DA, and 5-HT Analysis.........  71
xi
Figure Page
4-1 Concentration of Dopamine in Striatum 
as a Function of Microwave Irradiation
Time..................................  88
5-1 Daily Rhythms in NE, DA, and 5-HT Concen­
trations in Mouse B r a i n ...............  94
5-2 A Typical Chromatogram for Mouse Striatum. 102
5-3 A Typical Chromatogram for Mouse Cerebellum 103
CHAPTER I 
GENERAL INTROODCTION
Over the recent decades, information has accumulated
which suggests important roles for both the serotonergic
1 2and adrenergic nervous systems in the brain. ’ These 
systems utilize the indoleamine, 5-hydroxyptamine (5-HT, 
serotonin) , and the catecholamines, norepinephrine (NE) 
and dopamine (DA), as neurotransmitters.
Serotonin was first isolated from beef serum in 
1948, when it was demonstrated to exhibit vasoconstrictive 
activity.^ Shortly thereafter, its structure was identified 
to be that of 5-hydroxytryptamine.^ The material has since 
been shown to be widely distributed in nature. For example, 
many types of fruits such as pineapples and bauianas contain 
extremely large amounts of 5-HT. Also, many animal tissues 
contain significant amounts of serotonin.^ It is notably 
present in brain and innervated tissues, in blood platelets, 
and in intestinal mucosa.
All abbreviations used in the text are included in Appendix 
I for reference by the reader.
2
While serotonin does occur naturally in brain it does 
not enter the brain readily from the blood strezun because of 
its rejection by the blood-brain barrier. Therefore, the 
brain must synthesize its own serotonin (Figure 1-1). The 
first step in this synthesis involves the hydroxylation 
of the amino acid tryptophan to form 5-hydroxytryptophan 
(5-HTP) by the enzyme tryptophan hydroxylase (TPH). 5-HTP 
is then decarboxylated by 5-hydroxytryptophan decarboxylase 
to yield serotonin. Following synthesis, the major route 
of degradation for serotonin involves deamination® by the 
enzyme monocunine oxidase (MAO) to form 5-hydroxyindole- 
acetaldehyde. The aldehyde can be further oxidized to 
form 5-hydroxyindoleacetic acid (5-HIAA, the predominate 
product) or reduced to form 5-hydroxytryptophol. Enzymes 
have also been described in liver and in brain which can 
catabolize 5-HT without deamination through formation of 
the 5-0-sulfate ester.® This can then be transported out 
of the brain, possibly by the same acid excretion system 
handling 5-HIAA.
The catecholamines, norepinephrine and dopamine, 
are of increasing importance in many areas of neuroscience. 
Norepinephrine was first discovered in sympathetically 
innervated organs and sympathetic nerves by von Euler^ 
in 1946. It was also observed in urine and the adrenal
Qmedulla by Holts in 1947. Dopamine was ound in animals 
















FIGURE 1-1. Major metabolic pathways for the synthesis 
and metabolism of serotonin.
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These catecholamines are formed in brain, chromaffin
cells, sympathetic nerves, and sympathetic ganglia from
their amino acid precursor tyrosine by a sequence of
3-2enzymatic steps first postulated by Blaschko in 1939.
This sequence was finally confirmed by Nagatsu and coworkers^^ 
in 1964, with the demonstration that the last enzyme to 
be discovered (tyrosine hydroxylase) converted tyrosine 
to DOPA. The amino acid precursor, tyrosine, is normally 
present in the circulation in a concentration of about 
5 to 8 X 10  ̂M. It is taken up from the blood stream 
and concentrated within the brain and other sympathetically 
innvervated tissue by an active transport mechanism. Once 
inside the periperal neuron tyrosine undergoes the series 
of chemical transformations outlined (Figure 1-2), resulting 
in the ultimate formation of norepinephrine and dopamine.
Under normal conditions the biogenic amines are con­
tinuously being produced, released, and metabolized. Ab­
normal production and metabolism of these compounds may 
produce pathophysiological effects.^* For example, there 
is an increasing body of evidence indicating abnormal 
indoleamine metabolism in the affective disord e r s . A  
decrease in 5-HT and 5-HIAA concentrations has been reported 
in the brains of depressive suicides.Loss of brain 
serotonin has been associated with overeating and increased 
body weight.Lowering of 5-HT levels in both mêui and 















FIGURE 1-2. Biosynthesis of the catecholamines, norepi­
nephrine (NE) and dopamine (DA).
6
and external stimulae. These can involve disturbances of
sleepf increased susceptibility to convulsions, heightened
18sexuality, greater irritability, and aggressiveness. 
Elevations of serotonin in rats also showed marked behavioral 
changes.The involvement of catecholamines in affective 
disorders has been well established in the treatment of 
Parkinsons patients with L-DOPA to increase deficient 
brain dopamine levels.Recently, damage to the norepine­
phrine system of the brain has been postulated to have
21important implications in schizophrenia.
A great deal of recent research on biogenic amines 
attempts to separate the effects of each of the monoamines, 
NE, DA and 5-HT, in behavior and affective disorders.
This is usually done by comparing the monamine level in the 
brains of control animals to those pretreated with a drug 
or precursor, while observing the behavior of both groups. 
However, accumulating evidence strongly indicates that the 
catecholamines and indoleamine systems interact with each 
other as well as with other systems involved in neuro­
transmission, e.g., the cholinergic s y s t e m . A l s o ,  
it has been shown that the regional brain concentrations
of biogenic amines arc selectively affected by certain 
25drugs, and these regional concentrations, thus, may be 




Based on the above observations, an assay that can 
simultaneously determine both adrenergic and serotonergic 
neurotransmitters was deemed highly desireable. This assay 
should be selective, sensitive enough to analyse individual 
mouse brain parts, and inexpensive so that it can be used 
routinely-
The techniques frequently employed for the determina­
tion of biogenic amines in tissue samples^®”^® can all be 
broken down into three basic steps: (1) homogenization
followed by precipitation of macromolecules and subsequent 
removal by centrifugation, (2) isolation and purification 
of the biogenic amines, and (3) following physical separations 
of the biogenic amines or the division of the sample into 
two or more distinct samples, the separate quantitation 
of each species.
The initial precipitation step is usually performed 
by treatment with an acid. Isolation and purification of 
the amines has been accomplished by either liquid chromato­
graphic or extraction methods. The chromatography has
primarily utilized methodology similar to the cation exchange
27approach described by Taylor and Laverty. Extractions
have typically involved a pH adjustment, extraction into
a non-aqueous solvent, and a back extraction into an acidic
aqueous solution. Such an extraction procedure is des-
38cribed by Shore and Olin for the determination of
8
catecholamines. Catecholamines, of course, can also be
isolated by the highly selective alumina adsorption, as
41described by Anton and Sayre.
Finally, the detection and quantitation of the 
amines has been performed by fluorescence, gas chromatography 
(with or without mass spectrometry, GC or GCMS), and radio­
chemical techniques. The most commonly employed analyses 
have utilized fluorescence as a convenient mode of detection 
and quantitation. Although the fluorometric determinations 
of 5-HT may be performed directly in 3 M HCl, many workers 
seem to prefer derivatization with o-phthaladehyde, as 
used by Maickel et al.,^® or with ninhydrin, as introduced 
by Vcuiable,^^ to increase the sensitivity. The catecholamines, 
on the other hand, are chemically converted to indole
species by an oxidative rearrangement known as the trihydroxy- 
32indole method, prior to fluorometric determination.
This oxidative technique produces much more selective and 
intense fluorescence than the unchanged molecules and is 
still the method of choice. As mentioned, however, the 
determination of NE, DA and 5-HT by fluorometry usually 
involves chemical transformation to other compounds as well 
as the use of spectroscopically pure reagents and various 
other precautions to avoid possible interferences. The 
detection limit of the technique is only in the nanomole 
range. These restrictions frequently require sample pooling 
for the analysis of individual brain parts to obtain the
9
necessary sensitivity. Additionally, the selectivity of 
fluorescence in the quantitation of these samples leaves 
a great deal to be desired.
Gas liquid chromatography (GLC) with electron 
capture detection for the analysis of tissue samples
containing NE, DA, and 5-HT has been suggested by Arnold
34 35and Ford and others. Yet, the sensitivity limit ob­
tainable by this method was only ca. 50 ng/g of wet tissue 
for sample weights of 500 mg. The analysis time was also 
reported to be five hours for six samples. The combined 
technique of GCMS has been shown by Koslow et al.^® to 
be applicable to such determinations. While offering 
excellent selectivity and detection limits in the subpicomole 
range, GCMS is, undeniably, a very expensive technique to 
employ on a routine basis.
A rather recent entry into the area of biogenic 
amines determinations is the radiochemical techniques.
In these assays labeled S-adenosyl-L-methionine (methyl-^^ C 
or methyl-^H) and an appropriate methyltransferase enzyme 
e.g., catechol-O-methyltransferase (COMT) for the catechol­
amines, are incubated with the sample to convert the amine 
to a labeled methylated metabolite. The metabolite is then 
isolated by extraction into an organic solvent such as 
chloroform or toluene and assayed for ^^C or by scintilla­
tion counting. These enzymatic isotopic assays are highly 
specific, and sensitive to the picogram level. They have
10
been proven to be precise and reproducible. However, they 
do require careful hcmdling of reagents and cofactors as 
well as experience in working with enzyme preparations since 
they involve the use of purified enzymes which are not 
presently available commercially.
As one cêin readily observe, the highly sensitive 
assays for biogenic amines require the use of either the 
expensive GCMS or radiochemicals and scintillation counting 
equipment. Moreover, in all the techniques available, 
some form of chemical transformation is typically required 
which may add to the analysis error and lengthen the time 
required.
The technique of high performance liquid chromato­
graphy (HPLC) has provided rapid qualitative and quantitative 
analysis of mixtures. A major limitation in the wider 
application of this technique, however, has been the lack 
of sensitivity of the detection systems available.The 
most sensitive of these systems has previously been found 
to be ineffective for measuring nanogram and sub-nanogram 
quantities of catecholamines and indoleamines.
The development of the thin-layer electrochemical 
detector (EC) by Kissinger and coworkers^^ has provided 
the sensitivity and selectivity needed for the detection 
of many important biological and pharmacological compounds. 
This system has the capability of detecting as little as 
3 femtomole (fmole = 10~^^ mole) of some molecules.**
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The specificity of the detector is due to the fact that 
it can only "see" the confounds which are electrochemically 
active (capable of absorbing or releasing electrons) at 
the particular potential chosen. This selectivity is of 
great value in the analysis of complex biological tissues 
and fluids since most of biological compounds are not 
electrochemically active, a property which eliminates them 
from being possible interferences. Additionally, some 
of the interferences due to electrochemically active 
compounds can be eliminated by the particular choice of 
electrode potential. Moreover, the electrochemical detection 
has been shown^^ to exhibit a linear dynamic range of ca.
10^ to 10®.
High performance liquid chromatography combined
with electrochemical detection (LCEC) is now routinely
37used for the analysis of catecholamines. However, this 
37methodology cannot be directly applied to the analysis
of serotonin; the catecholamines in this technique are
isolated by their highly specific adsorption onto alumina,
a procedure which will eliminate serotonin due to its lack
of similar adsorption. Simultaneous determination of
serotonin and the catecholamines has been accomplished
38by extraction at a low pH value and by a few, essential 
modifications in the previous LCEC system. Details of 
development of the methodology will be discussed later.
In short, the present dissertation is primarily
12
a report of the development of two new, major biogenic 
amine assays: (1) the simultaneous determination of DA
and 5-HT, and (2) the simultaneous determination of NE,
DA, and 5-HT. The sensitivity of these methods permits 
direct application to individual small parts of mouse 
brain. Chemical conversion prior to measurement of the 
biogenic amines has been eliminated and, in comparison 
to the previous techniques, substantially less initial 
monetary investment is required. Additionally, this 
methodology, utilizing LCEC, provides sensitivity and 
selectivity comparable to that of the exquisite GCMS, 
Finally, to demonstrate the broad applicability of these 
assays, a variety of practical neurochemical investigations 




Generally, all chemicals were used without any
further purification. Both reagent grade n-butanol from
Mallinckrodt and n-butanol purified according to Shore 
38and Olin (by successive washings with 1 M HCl, 1 M NaOH,
and deionized water) were examined for use in the extraction.
Likewise, Baker analyzed n-heptane and heptane purified
38according to Shore and Olin were investigated. Ethylene- 
diaminetetraacetic acid dihydrate (EDTA) was obtained as 
the disodium salt from Fisher Scientific. Sodium chloride 
was reagent grade from Mallinckrodt. The biogenic amines,
NE as norepinephrine hydrochloride, DA as dopamine hydro­
chloride, and 5-HT as serotonin creatinine sulfate mono­
hydrate, were purchased in the highest possible purity 
from Aldrich and Regis Chemical Cos., respectively. All 
concentrations of these compounds are expressed as the 
free base. The internal standard, 3,4-dihydroxybenzyl- 
amine«HBr (DHBA, 98% pure) was obtained from Aldrich. The 
alternate internal standard, a-methyIdopamine-HBr, (o-MeDA)
13
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was prepared in our laboratory according to Borgman et al.*^ 
All other compounds tested for possible interference in 
the procedure, were obtained in the highest possible purity 
from Regis Chemical Co. Ascorbic acid was obtained from 
Aldrich. The components of the mobile phase, i.e., sodium 
acetate, acetic acid, sodium hydroxide, and citric acid, 
were all reagent grade from Mallinckrodt. All water used 
was deionized.
The stock standard solution, containing ca. 40 yg/ml 
NE, 90 yg/ml DA and 65 yg/ml 5-HT, was prepared by dissolving 
the appropriate amount of their salts, accurately weighed, 
in 100 ml of 0.01 M HCl. The HCl was previously deaerated 
for 15 minutes with O^-free N^. This solution was stable 
for up to one month if stored in the refrigerator at 4®C. 
However, we never utilized a solution stored for more than 
two weeks. The working standard solution was always pre­
pared on the day of use by diluting a 1 . 0 0  ml aliquot of 
the stock standard solution to 100 ml with deaerated 0.01 M 
HCl. Thus, the working standard contained ca. 400 ng/ml NE, 
900 ng/ml DA, and 650 ng/ml 5-HT. This is comparable to the
whole brain concentrations (expressed as ng/g tissue).
The internal standard, a solution of ca. 10  ̂M 
DHBA, was prepared by dissolving the appropriate amount of
^Described in Section 2 of this chapter.
15
the hydrobromide salt of DHBA in deaerated 0.01 M HCl.
The concentration of the internal standard need not be 
accurately known provided that the same volume of the same 
solution is added to both the standards and the samples.
This solution was also stable up to one month when stored 
at 4*C. Lower concentrations of DHBA were used in the 
determination of mouse brain parts and are clearly noted 
in that section of the text.
Ascorbic acid solution was always prepared im­
mediately before use by dissolving 1 1  mg in 1 ml of 0 . 0 1  H 
HCl. Lower concentrations of this solution were utilized 
with the standcird solutions employed in the determinations 
of brain parts. These concentrations will be clearly noted 
in the final assay for brain parts.
The mobile phase finally selected for the LCEC, a 
pH 5.1 acetate/citrate buffer, was prepared by dissolving 
8 . 2  g anhydrous sodium acetate, 2 . 1  ml glacial acetic acid, 
4.8 g sodium hydroxide, and 10.5 g of citric acid monohydrate 
in 1 liter of water. Before use, it was filtered through a 
0.45 micron Millipore filter to prolong pump life and to 
avoid column blockage by any particulate matter.
2. LCEC Apparatus;
The liquid chromatograph was constructed entirely 
from separate components. A simplified drawing of the basic 







FIGURE 2-1. Apparatus for liquid chromatography with 
electrochemical detection.
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sufficiently free of oxygen, it must be "scrubbed" by passing 
it through two gas washing bottles in series containing 5% 
chromous perchlorate in 10% perchloric acid.*^ The pumping 
system utilized was a Milton Roy reciprocating minipump 
(max. flow-rate, 160 ml/hr, max. pressure, 5000 p.s.i.).
This pump was connected to a coil (ca. 25 m) of 0.8 mm 
diameter Teflon tubing to partially dampen pulsations.
The injection ports and standard connectors were 
obtained from Altex Scientific, Inc. (Berkeley, California). 
The glass columns, also availedjle from the same supplier, 
were 2 mm dicuneter by 500 mm length, 3 mm diameter by 500 mm 
length, and 3 mm diameter by 250 mm length. These columns 
were packed with a pellicular strong cation exchcuige resin: 
typically, either Zipeuc SCX from DuPont (Wilmington,
Delaware) or Vydac SCX from the Separations Group (Hesperia, 
California) were employed. Specifically, the columns 
finally shown to be most useful for the DA/5-HT assay 
were a 3 mm diameter by 250 mm length unit connected through 
a minimum dead volume fitting to a second unit, 3 mm 
diameter by 500 mm length, both columns being packed with 
Zipax SCX. For the NE/DA/5-HT assay, the columns used 
were: a 3 mm diameter by 250 mm length unit packed with
Zipax SCX in tandum with 2 mm diameter by 500 mm length 
unit packed with Vydac SCX. Chromatographic injections 
were made with micro syringes (Hamilton CR 700-50) fitted 
with 20 gauge platinum needles. The needles are available
18
from the same supplier and are not particularly expensive.
The detector (Figure 2-2) was simply two blocks 
of lueite, each 44 mm in length, 35 mm in width, and 12 
mm in thickness (these dimensions are not critical). The 
two blocks were separated by a thin (0.1 mm) Teflon spacer 
cut from commercial sheet supplied by Small Parts, Inc. 
(Miami, Florida). This spacer, shown separately in Figure
2-2-C, has a slit 2 mm wide and 25 mm long, cut in it.
One of the blocks (the left side of Figure 2-2-A) has 
two holes, cut at the approximately indicated angles, to 
provide an inlet (In) and outlet (Out) flow stream from 
the column through the Teflon slit region. These holes 
were drilled slightly oversized emd standard 0.8 mm Teflon 
tubing was inserted in each. The tubing was sliced flush 
at the inner face of the block and the excess was trimmed 
smooth with a razor blade. The upper end of the inlet 
tube was connected to a standard diameter Altex male tubing 
connector which was recessed and secured with epoxy cement 
to the top of the block.
The opposite block (right side of Figure 2-2-A) 
contained a recessed well of ca. 5 mm diameter and 9 mm 
in depth. Again, the well dimensions are not critical.
It should, however, be slightly greater in diameter than 
the spacer slit width auid positioned slightly downstream 
of the point where the inlet tube emerges from the opposite 










FIGURE 2-2. Carbon-paste electrochemical detector.
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a drill hole into which a platinum wire contact was sealed 
(the platinum wire is shown as a solid black dot emerging 
perpendicular to the page in Figure 2-2-A). The well 
was packed flush to the rim with carbon paste (will be 
described later in this section) which forms the working 
electrode surface. The Incite block with the carbon paste 
well was then rubbed to a smooth surface on computer cards.
Figure 2-2-D shows the connection from the outlet 
tube of the carbon paste detector to the overflow unit, 
a 125 ml suction flask fitted on the top with a rubber 
septum. The reference electrode (saturated calomel electrode, 
SCE) cind the auxiliary electrode (a platinum wire) were 
inserted in. holes pierced through the septum to dip into 
the overflow solution providing the three electrode cell.
The side arm of the section flask was then used as the 
natural overflow outlet for the chromatographic system.
The carbon paste for the working electrode was 
made by thoroughly mixing 3 g of Ultra Pure Graphite (UPG) 
powder (Ultra Carbon Corp., Bay City, Michigan) with 2 ml 
of Nujol. Thorough mixing requires considerable time, 
but a single batch suffices for many electrodes.
The electronics used to control the potential of
the working electrode and monitor the current have been
47previously described. The potential controller, in­
cidentally, is now commercially available from the Bio- 
analytical Systems Inc. (West Lafayette, Indiana). The
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outputr directly proportional to the current flowing in the 
carbon paste electrode, was monitored as a function of time 
by directing it to an Omniscribe (Houston Instruments, 
Austin, Texas) single pen recorder.
3. Animals;
Mice used in the various investigations were adult
males of the ARS-HA/ICR strain (Sprague-Dawley, Madison,
Wisconsin) weighing 20-30 grams at the time of sacrifice.
These were maintained in 12 hr. dark/12 hr. light cycle
(lights on from 0700 to 1900 hr.) and allowed access to
food and water ad libitum. No mice were employed in the
experiments until, at least, one week after their arrival
so that they could become accustomed to these conditions.
Also, since diurnal fluctuation in the biogenic amine
49levels was reasonably expected, the animals were only 
sacrificed at a fixed time each day (10:00 - 10:30 a.m.).
The mice were sacrificed by cervical dislocation.
The brains were removed as rapidly as possible, frozen in 
liquid Ng,.and stored on dry ice. Each brain was weighed 
to the nearest mg and transferred to 30 ml screw-cap vial. 
The vials were kept on dry ice during the addition of 
reagents. When brain parts were to be analyzed, the whole 
brain was placed on an ice cold glass plate for dissection 
immediately after removal. The seven peirts (cerebellum, 
medulla-pons, midbrain, diencephalon, hippocampus, striatum.
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and cortex) were then removed by a procedure described in 
detail by Wassil.^® The author is indebted to Mr. David 
Wassil (Chemistry Department, Oklahoma University) and Ms.
Joyce Valkovitch (Pharmacology, Health Sciences Center, San 
Antonio, Texas) for providing all the brain parts included 
for this work.
4. Centrifuge;
The centrifuge employed was a refrigerated centrifuge 
(Sorvall RC-2B) with an SM-24 rotor. The Teflon centrifuge 
tubes, each 15 mm diameter by 100 mm length and having a 
round bottom, employed were from DuPont Instruments (Wilmington, 
Delaware).
5. Shaker:
An Eberbach shaker, operated at 280 cycles/minute 
and immersed in an air bath at 15*C, was employed for the 
extractions. Vials were always placed on their sides with 
the long axis parallel to the direction of shaking.
6. Microwave Oven:
Sacrificing animals by microwave exposure was kindly 
performed by Dr. William Stavinoha's group at the Health 
Sciences Center in San Antonio, Texas. For properly focusing 
the beam of radiation, the animal had to be placed in a modi­
fied 50 ml plastic syringe- For enzymatic deactivation (and 
killing), the head was exposed to 6 kw of microwave irradiation 
at 2450 MHz for 250 msec unless clearly noted otherwise.
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7. Tissue Homogenizers;
All brain tissue ScUî les, unless otherwise noted, 
were homogenized with an ultrasonic homogenizer (W200P, 
Ultrasonics, Inc.) equipped with a long probe tip for small 
volume work. A ground glass homogenizer (Kontes-Martin) 
was also briefly used in an investigation of the possible 
ill effects of ultrasonic treatment on 5-HT levels.
8 . Calculations:
Whenever an assay was performed, working standard 
samples were always treated exactly like the tissue samples. 
The calculations were then based on the peak height ratios 
of NE, DA, and 5-HT, respectively, to DHBA in standard 
samples vs. the same ratios in brain samples. A typical 
calculation (for DA) is given as:
._ _ _ peak height, DA
peak height, DHBA
Results of a typical analysis are tabulated below. The 
sample data are taken from the peak heights of a whole 
mouse brain determination. The actual standard utilized 
contained 274 ng of DA. The exact calculation for DA 
content is:
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Peak Heights (mm) Peak Heights Ratios
DA DHBA DA/DHBA
Standard 99 106 0.934
Brain Sample 132 102 1.294
(wt. 0.462 g)
(C462) = 819 «9/?
37This is similar to the calculation of Refshauge et al. 
in the analysis of catecholamines.
An important point to be noted here concerns the 
addition of an internal standard to both brain samples 
and working standards. This eliminates the need to reproduce 
the injection volumes, since only peak height ratios are 
used in the calculations. Also, the working standards 
are subjected to exactly the same extraction procedure 
as tissue samples. Thus, the final results do not need 
to be corrected for percent recovery except when this 
percent recovery is different for the working standards 
and tissue samples (i.e., for 5-HT as will be shown in 
Chapter 3).
For calculations of percent recovery, the peak 
heights of the individual amines were first established by 
injection of a saitçle of the mixture to be extracted.
Then the percent recovery was determined by proceeding 
through the steps of the extraction procedure. The heights 
before and after extraction, obtained with the same
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injection volume, were then compared. The results were 
corrected for dilution as follows:
percent recovery =
peak height after extraction final volume 
peak height before extraction initial volume
All uncertainties for multiple determinations were 
expressed as the standard error of the mean (SEM), since 
this is the usual parameter applied to such determinations. 
Statistical levels of significance were calculated using 
the student's t-distribution.
CHAPTER III
DEVELOPMENT OF BIOGENIC AMINES 
LCEC ANALYSES
A. Initial Chromatographic Studies
The major goal of this research was to develop a 
more sensitive, selective, and widely applicable technique 
for the analysis of the biogenic amines (NE, DA, and 5-HT). 
This assay should be performed relatively rapidly to allow 
the maximal amount of sarnie throughput. Therefore, an 
intensive search for a rapid and efficient chromatographic 
separation of these compounds was undertaken. Preliminary 
investigations utilized a synthetic whole brain mixture 
of the biogenic amines, ca. 10~® M each, and ascorbic acid, 
ca. lO”  ̂M, dissolved in deaerated 0.01 M HCl. Ascorbic 
acid was added to mimic brain ascorbic acid levels and 
retard oxidation of the amines.
Since these biogenic amines are known to have pKy 
values of ça. 5̂  they may be considered to be fully pro- 
tonated at pH values < 7. But, these species are also known 
to be highly sensitive to oxygen, very unstable in aqueous 
alkaline solution, and relatively stable at acidic pH
26
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values.^ Therefore, a deaerated, acidic eluting solvent
appeared chromatographically most reasonable. Also, for
these same reasons, the choice of a cation exchange resin
for preliminary studies was a quite logical choice as the
chromatographic packing material.
Our first choice for a column packing was Zipax
SCX. This decision was primarily based upon two facts:
(1 ) this material had already provided a baseline separation
in the assay for catecholamines (NE and DA) developed by 
47Refshauge employing 0.1 M perchloric acid as a mobile 
phase, (2) Zipax SCX is unique among strong cation exchangers 
in having a fluoropolymer backbone (all others have some 
type of silica or polystyrene-divinylbenzene backbone).
Our first attempt at obtaining the desired chromato­
graphic separations thus utilized various column lengths 
(500 to 1000 mm), various flow rates (to ca. 2 ml/min), 
and various concentrations of the eluting solvent, HCIO^
(0.05 to 0.20 M). The flow rate maximum, it should be 
noted, was effectively controlled by the pressure; the 
glass/Teflon system can only be reasonably operated for 
extended periods of time at a pressure of < 800 p.s.i.
Two major difficulties arose under these conditions. 
First, ascorbic acid, being predominately uncharged at 
these pH values, was not retained by the column. Thus,
A fluoropolymer based packing with -SO3 as a functional group 
and a particle size of 30-40 urn.52
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at flow rates reasonable for rapid analysis, it always
*comprised a rather large "solvent front" which significantly
overlapped with the only slightly retarded NE. The second
47problem was that the anomalous iron peak observed in 
this acidic medium (as Fe^) was almost completely isographic 
with serotonin. Neither of these problems could be 
adequately resolved by the adjustments of chromatographic 
parameters mentioned above. Additionally, the same problems 
were again encountered when the solvent used in the analysis 
of tyrosine hydroxylase activity by Pike^^ was employed.
This solvent was composed of 0.03 M HCIO^ containing 0.025 M 
KClOj.
Being still confident that Zipax could achieve 
the desired separation, we moved a step further in trying 
to remove the Fe^ by adding to the mobile phase some reagent 
that could complex this interference. In the complexed 
form, it would either be no longer electrochemically active 
due to a shift in oxidation potential or, at least, it 
would no longer exhibit the same retention time due to a 
change in its charge and/or structure. Therefore, we 
first added o-phenanthroline and then EDTA (each to a con­
centration of 0.002 M) to the 0.1 M HCIO^ eluting solvent.
*This "solvent front" was shown later by the study of inter­
ferences to be due not only to ascorbic acid but also to 
the acidic and neutral metabolites of both catecholamines 
and indoleamines as well as other unidentified tissue 
components.
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But the anomalous Fe"*"*" peak was still present and isographic 
with serotonin. Looking for possible chloride complexation, 
we also tried the following eluting solvents; 0.1 M KCl 
in 0.01 M HCl and 0.1 M NaCl in 0.01 M HCl. Again, both 
proved to be unsuccessful in achieving the desired separation 
or elimination of Fe^. Employing solutions of 0.1 to 0.2 M 
oxalic acid, which is known to complex Fe** in the oxalate 
form in moderate to high pH values, did not result in any 
better results. Citric acid solutions (.05 to 0.2 M) 
ended in the same lack of success.
At this point, it became quite obvious that the 
use of Zipax SCX with an acidic eluting solvent would con­
tinually present us with the Fe^ problem. A quite obvious 
choice, therefore, was to examine eluting solvents of a 
higher pH value. To our surprise, and a happy surprise 
it was, the Fê"*" peak simply disappeared from the chromato­
grams when the eluting solvent had a pH > 3. That this 
effect was not due to the choice of buffer materials was 
shown by reproducing the result for each of acetate, 
phosphate, citrate/phosphate, and acetate/citrate buffer 
combinations (all with pH > 3). For further investigations 
we selected the pH 5.1 citrate/acetate buffer^^ previously 
mentioned in the experimental section. This section was 
based upon three criteria: (1 ) it had previously^^ been
shown to provide a reasonably rapid separation of the 
biogenic amines and some of their metabolites on a Bondapak/
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Corasil strong cation exchange (Waters Associates, Milford, 
Massachusetts) packing; (2) it eliminated the Fe** problem; 
cind (3) preliminary investigations showed that, in combina­
tion with Zipax SCX, this buffer provided almost ideal re­
solution of the individual biogenic amines.
Optimal Chromatographic Conditions for DA/5-HT Analysis
Having selected an adequate column packing/eluting 
solvent combination, we proceeded to optimize the various 
chromatographic conditions for biogenic amine analyses- The 
following parameters were found to provide both a baseline 
separation of DHBA, DA, and 5-HT and the shortest possible 
time between injections; (1) a Zipax SCX strong cation ex­
change resin, 3 mm diameter by 750 mm length, (2) the pH 5.1 
citrate/acetate buffer as a mobile phase, (3) a flow rate of 
ca. 1.3 ml/min, which yielded a pressure of ca. 600 p.s.i.,
(4) a working electrode potential of +0.60 volts vs. SCE. 
Utilizing these conditions, individual injections could be
made every 1 0  min; and, this analysis time was effectively
45halved by employing the dual parallel apparatus of Blank.
NE was not sufficiently separated from the solvent front under 
the optimal conditions to allow its simultaneous quantitation. 
Much slower flow rates or greatly weakened (diluted ca. 1:10) 
eluting solvent did yield an NE/solvent front separation. But 
these conditions would make the time between injections approach
DHBA was initially selected as the internal standard due to its 
chemical similarity to the biogenic amines and its excellent 
chromatographic properties.
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1 hr., a clearly unacceptable throughput. However, the 
importance of DA and 5-HT alone warranted the further 
development of an analysis for these two species.
Investigation of Chromatographic Interferences in the 
DHBA/DA/5-HT Separation
Before esteiblishing an appropriate isolation pro­
cedure for the nervous tissue analysis of DA and 5-HT, 
it was decided that possible chromatographic interferences 
should be examined. There are, in fact, a relatively small 
number of components which would feasibly interfere with 
the projected assay. Such species (1) must be carried 
through the isolation procedure to be developed, (2 ) must 
have a percent recovery and endogenous concentration suf­
ficient to yield a final molar concentration at least 
within a factor of 100 of the determined compounds, (3) must 
be retained by the cation exchange resin, and (4) must be 
electrochemically active on the carbon paste electrode at 
+0.60 V vs. SCE in this medium. The most likely candidates 
are, thus, the basic metabolites in the catecholamine and 
indoleamine biosynthetic pathways. We also investigated 
neutral metabolites, acidic metabolites, and ascorbic 
acid. The results of these investigations are presented 
in Table 3-1.
Ascorbic acid fulfills all the requirements for 








Ascorbic acid 2.5 1 . 0
3,4-Dihydroxyphenethyl alcohol 2.5 1 . 0
3,4-Dihydroxyphenylglycol 2.5 1 . 0
L-3,4-Dihydroxyphenylalanine (DOPA) 2 . 0 0.7
L-3-O-Methyl DOPA 2.5 1 . 0
3,4-Dihydroxyphenylacetic acid 2.5 1 . 0
3,4-Dihydroxymandelic acid 2.5 1 . 0
3,4-Dihydroxyphenylalanine 2 . 0 0.7
5-Hydroxytryptophan 2 . 2 1 . 1
Norepinephrine 2 . 6 1 . 0
Normetanephrine 4.0 2 . 0
Dihydroxybenzylamine 4.0 2 . 0
Epinephrine 5.2 2.3






Metanephr ine 23.0 8 . 0
3-Methoxytyramine 46.0 17.0
4-Methoxy-3-hydroxyphenethylamine 6 8 . 0 2 0 . 0
Chromatograms of these compounds were only obtainable at 
a voltage of +0.94 V vs. SCE.
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and, thus, forms a major portion of the solvent front 
(t^=2.5 min). Aromatic amino acids, including 3,4-dihydroxy- 
phenylalanine and 5-hydroxytryptophan, are all in the 
zwitterion form at the pH of the eluting solvent. Thus, 
they also elute on the solvent front. Tyrosine and tryptophan, 
incidentally, are not observed because of their inability 
to be oxidized at this potential. Both 3,4-dihydroxyphenethyl 
alcohol and 3,4-dihydroxyphenyl glycol (neutral metabolites) 
elute under the solvent front. 3,4-Dihydroxyphenylacetic 
acid and 3,4-dihydroxymandelic acid, acidic catecholamine 
metabolites, also appear under the solvent front.
Biogenic amines related to DA and 5-HT comprise 
another group examined. Norepinephrine (NE) is slightly 
separated from the solvent front. But because of the large 
tissue concentrations of ascorbic acid, NE is effectively 
buried and, unfortunately, not determinable. Epinine 
(N-methyIdopamine) is completely separated (t^=18.5 min) 
from the 5-HT peak (t^=9.3 min) and the procedure could 
be utilized directly to determine this species in appropriate 
samples. Tryptamine is not detectable at the potential 
chosen; but chromatograms run at +0.94 V vs. SCE display 
a very broad peak for tryptamine at t^=24.5 min. Epinephrine 
(E) elutes (t^=5.2) almost directly between DHBA (t^=4.0 min) 
and DA (t^=6.2 min), but is rather poorly resolved (R=0.77 
and 0.67, respectively). However, E is normally present 
in brain tissue in only very small amounts. Even if present
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in equimolar concentrations with DA, E would contribute
only ça. 6 % to the measured peak height for the former-
Thus, as long as E cemnot be visually detected in the
chromatography of saitç>les, it will not present any major
problems. Quantitative separation of DA and E can, if
necessary, be accomplished by either diluting the citrate/
acetate solution solvent or utilizing the column conditions
47reported by Refshauge.
Methoxylated metabolites form the other major group 
examined. 3-Methoxy-4-hydroxyphenylalanine (3-0-methyl- 
DOPA) elutes with the solvent front as do the other amino 
acids. 5-Methoxytryptamine is not electrochemically active 
at the potential chosen; however, it does exhibit a broad, 
poorly resolved peak (tĵ =28.0) at a potential of +0.94 V 
vs. SCE. Metabolites which are observed under the given 
conditions include normetanephrine (t^=4.0 min), 3-methoxy- 
tyramine (3-MT, t^=46 min), 4-methoxy-3-hydroxy- 
phenethylamine (t̂ = 6 8  min), and metanephrine (t^=23 min).
Of these, only normetanephrine, which is isographic with 
DHBA, is of concern. The other species are clearly 
separated from the components of interest; also, their 
endogenous concentrations are generally so low that they 
are not observed in routine determinations. Normetanephrine 
(NMN), as the other methoxylated catecholamines, is only 
partially oxidized (ca. 15% relative to maximum obtainable) 
at the potential chosen. Additionally, NMN is present
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in brain tissue at relatively low concentrations (65*4 ng/g, 
personal observation). Mouse brain determinations in 
which DHBA was omitted showed no discernible NMN peak at 
the sensitivity employed (less than 1% of the usual DHBA 
peak). Thus, NMN should not normally cause any significant 
interference.
Since both NMN and E overlap the chosen internal 
standard, other species were investigated for possible use 
in samples where either of these may pose problems. a-Methyl- 
dopamine (a-MeDA, t^=18.5 min) was found to be quite adequate 
for this purpose. But, one should remember that this will 
increase the time required for individual determinations.
Also, o-methyldopamine is isographic with epinine.
In short, however, there are no major known inter­
ferences in the procedure.
Development of Optimal Chromatographic Separation for NE/DA 
and 5-HT Analysis
As shown in the interferences study discussed im­
mediately above, NE was "buried" under the "solvent" peak.
A separation of HE, DA, and 5-HT was still desired to expand 
the capabilities of LCEC to include all three components 
simultcuieously. Therefore, chromatographic conditions 
capable of attaining the adequate resolution of these 
species in a reasonable period of time were sought.
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Preliminary investigations utilized Partisil-10 
SCX and the same pH 5.1 citrate/acetate buffer diluted 
to 40% of its original concentration by deionized water.
These investigations showed all three of the biogenic 
amines to be strongly retarded and thus, adequately separated 
from the "solvent" peak. But, the individual amines were 
poorly resolved. Also, the use of the metal column, in 
which this packing was provided, in direct conjunction 
with the electrochemical detector contributed a substantial 
amount of electronic noise to the base line.
Therefore, it was decided to use the Partisil-10 
SCX metal column in tandem with a glass colmnn of 2 mm 
diameter by 250 mm length packed with Zipax SCX. This 
combination, with the use of the diluted (40%) pH 5.1 
citrate/acetate buffer as an eluting solvent achieved 
the separation desired and the noise was considerably re­
duced. One shortcoming appeared to be the relatively low 
analysis time involved (ca. 32 min per injection). Yet, 
the separation was worth considering for direct injection 
of tissue homogenates.
The direct brain injection analysis included homo-
This is a cation exchcUige resin of 10 vm particle size. It 
contains a silica gel backbone with -SO3 functional groups.^2 
The column utilized was a metal column of 4.1 mm diameter by 
250 mm length supplied by Altex Scientific Corporation, 
Berkeley, California. Unfortunately, this material cannot 
adequately be packed in a glass column due to the very 
small particle size.
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genization of the brain tissue in 0.1 M HCIO^, centrifugation, 
and single injection of a part of the supernatant into 
the chromatographic system. Such an assay would be very 
fast since it does not require any chemical manipulation, 
extraction, and/or adsorption. The selectivity and the 
sensitivity of the LCEC system makes such an assay appear 
at the outset to be quite feasible. Thus, we decided to 
investigate this procedure for the possible routine deter­
mination of the biogenic amines.
Unfortunately, the system utilized for direct 
analysis provided, in routine application, a far more 
serious problem than just finding the initial separation 
conditions. After only a minimal number of analyses, the 
cation exchange resin (particularly the Zipax SCX) was 
observed to significantly deteriorate as shown in Figures
3-1 and 3-2. Since ten (or less) injections was deemed 
an unacceptable column life, this approach was abandoned.
Simultaneous to this investigation we decided to 
try the same Partisil-10 SCX/Zipax SCX combination at a 
higher pressure (ca. 2500 p.s.i.) coupled with a weaker 
ionic strength of the same citrate/acetate buffer (diluted 
1:3 with deionized water). This attempt, although it 
provided the desired separation in a reasonable time as
For this investigation the pump utilized was a high pressure 
pump model 6000 from Waters Associates, Inc., Milford, 
Massachusetts. The pump was coupled to Model 06K injector 







FIGURE 3-1. A typical whole mouse brain chromatogram, direct 
brain injection (50 vl of homogenate supernatant) 
Eluting solvent; citrate/acetate buffer diluted 
2:3 with deionized water, electrode potential 








FIGURE 3-2. A whole mouse brain chromatogram after less than
10 direct injections (each was 50 yl of homogenate 
supernatant). Same conditions as Figure 3-1.
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shown by the chromatogram of Figure 3-3, exhibited even 
more difficulties. With only the synthetic brain mixture 
of ascorbic acid, NE, DA, and 5-HT, it was obvious that 
the quantitation of NE would be impossible due to the 
anomalous solvent front behavior. Additionally, the base 
line exhibited an unpredictable and inexplicable amount 
of electrical noise which significantly decreased the 
sensitivity of the detector. Therefore, this high pressure 
approach was tec^rarily abandoned.
At this stage, it was obvious that the best re­
solution of the individual components was provided by the 
fluorocarbon based Zipax SCX resin. Yet, this same material 
was inadequate in providing sufficient separation of NE 
from the solvent front. The silica based strong cation 
exchangers (as represented by Partisil-10 SCX), on the 
other hand, elicited just the opposite behavior: adequate
NE/solvent front separation but inadequate resolution of 
individual amines. And, the metal columns in which Partisil- 
10 SCX is obtained, led to unacceptable levels of background 
noise. Thus, we began to investigate other packing materials 
to replace the Partisil-10 SCX in the above Zipax/Partisil 
combination. All the materials examined were selected to 
have a particle size (30-40 pm or greater) sufficient to 
allow hand packing into glass columns, thus eliminating 









A typical LCEC chromatogram employing the 
high pressure system; 2500 p.s.i., flow 
rate ca. 2.5 ml/min, 50 yl injection. 
Eluting solvent was citrate/acetate buffer 
diluted 1:3 with deionized water.
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High Capacity Pellionex SCX proved to be inadequate 
for our purposes. The resolution of solvent front from 
NE as well as that for each of the individual amines was 
extremely poor. Eluting solvents tried included: the
**pH 5.1 acetate/citrate buffer, a pH 5.0 Mcllvaine buffer, 
and a 0.2 M NaH^PO^ solution of pH 4.2. Each of these 
attempts clearly showed that, in addition to the poor re­
solution noted, extremely long analysis times were required. 
Thus, Pellionex was discarded as a possible answer to 
our problem.
Another polystyrene-divinylbenzene copolymer packing 
tried was Vydac SCX (see Chapter 2). This packing, in 
combination with the pH 5.1 citrate/acetate buffer provided 
considerable success in the separation of the solvent 
front and NE peaks, yet it achieved a very poor resolution 
for the NE, DHBA, DA, and 5-HT peaks. Therefore, a combina­
tion of the two packings (Zipzix and Vydac) was deemed worthy 
of investigation.
This is a cation exchange resin of 37-53 um particle size. 
Its structure is a polystyrene-divinylbenzene copolymer 
backbone with -SO3 functional groups.^2 it was supplied 
by Reeve Angel and Co., Inc., New Jersey.
**Prepared by dissolving 73.6 g NagHPOa'lZH^O, 20.4 g 
citric acid monohydrate, and 36.4 g NaCl in 1 liter of 
deionized water.
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Optimal Chromatographic Conditions for NE/DA/5-HT Analysis
By employing various column lengths, flow rates, 
and ionic strengths of the mobile phase, we were able to 
optimize chromatographic conditions for NE/DA/5-HT analysis. 
These optimal parameters were as follows. The columns 
consisted of a 3 mm diameter by 250 mm length Zipax SCX 
unit in combination with a 2 mm diameter by 500 mm length 
Vydac SCX unit. The elution solvent was the pH 5.1 citrate/ 
acetate buffer (see Chapter 2) diluted to 60% of its previous 
ionic strength with deionized water. The flow rate was 
reduced to ca. 0 . 6  ml/min resulting in a pressure of ca.
600 p.s.i. The potential was kept at +0.60 V vs. SCE.
Later application of these chromatographic conditions 
to the analysis of brain tissue clearly exhibited the 
applicability of these parameters to the quantitation of 
NE, DA, and 5-HT.
Unfortunately, under these conditions, 5-HT is 
relatively more strongly retarded by the Vydac SCX than 
the catecholamines NE, DHBA, and DA. Therefore, the 
total analysis time is ca. 22 min per sample. Yet, this 
time can be effectively halved by employing the dual 
parallel apparatus previously mentioned.*^ Operating with 
the dual system, thus, provides analysis of all three biogenic 
amines within a relatively reasonable period of time.
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Investigation of Chromatographic Interferences in NE/DHBA/ 
DA/5-HT Separation
Since the chromatographic conditions utilized 
for this separation were different from the DA/5-HT con­
ditions, it was essential to reinvestigate the possible 
interferences. Table 3-2 lists the compounds investigated 
according to their elution order.
On the basis of conditions required for a compound 
to interfere (see previous investigation of DA/5-HT in­
terferences in this chapter) the only compounds of concern 
are: normetanephrine (NMN, t^=6 . 6  min), which elutes between 
DHBA (tĝ =5.5 min) and DA (t^=8.0 min); metanephrine (M, 
t^=16 min); 3-methoxytyramine (3-MT, t^=27.0 min); and 
epinine (t^=15.0 min). However, NMN and M both are again 
only partially oxidized (ca. 15% of the maximum possible) 
at thé potential chosen. Additionally, NMN and M are 
present in brain tissue at relatively low concentrations 
(NMN=65±4 ng/g, personal observation, and M is not de­
tectable^^) . 3-MT elutes directly after 5-HT, yet its 
peak height in brain tissue samples is normally less than 
5% of those of the biogenic amines zmd, thus, causes no 
major interference. 3-MT can be quantitated, although 
the analysis time will be extended to 30 min. A typical 
whole mouse brain chromatogram with 3-MT, is provided later. 
In short, however, there are no significant interferences 








3,4-Dihydroxyphenethyl alcohol 2.4 1 . 2
3,4-Dihydroxyphenyl glycol 2.3 1 . 1
3,4-Dihydroxyphenylacetic acid 2.3 1 . 2
3,4-Dihydroxymandelic acid 2.3 1 . 2
3,4-Dihydroxyphenylalanine (DOPA) 2.3 1 . 2
1,-3-0-Methyl DOPA 2.3 1 . 1
5-hydroxytryptophan 2.3 1 . 2
Norepinephrine 3.5 1 . 0
Dihydroxybenzylamine 5.5 2 . 0
Normetanephrine 6 . 6 2.3
Dopamine 8 . 0 3.0
5-Hydroxytryptamine 2 0 . 0 5.0
Tryptamine^ 31.0 30.0
Epinine (N-methyldopamine) 15.0 5.0
Metanephrine 16.0 6 . 0
5-Methoxytryptamine^ 2 1 . 0 33.0
3-Methoxytyr amine 27,0 6 . 0
4-Methoxy-3-hydroxyphenethylamine 41.0 13.0
^All compounds (except two^) investigated with the column 
conditions described in the text and used for routine analysis.
^Chromatograms of these two compounds were only obtainable 
at a voltage of +0.94 V vs. SCE.
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B. Isolation Procedure
In the previous investigation of brain tissue
analysis based on direct injection into the LCEC it was
noted that the Zipax SCX column packing deteriorated after
only a few injections. This deterioration is assumed to
be due to some endogenous tissue components which can
"poison" the chromatographic column packing. Therefore,
a procedure for the isolation of these biogenic amines
from these endogenous con^nents was necessary.
The isolation of catecholamines NE and DA (but
not the indoleamine 5-HT) by adsorption onto alumina at
41pH=8 . 6  is known to be highly selective. Yet, it was 
thought that 5-HT might also be isolated by AlgOg adsorption 
at pH < 8 .6 . Thus, alumina adsorption followed by acid 
elution was attempted as a method to extract all three of 
the biogenic amines NE, DA êmd 5-HT from synthetic aqueous 
solutions of pH values ranging from 2 to 8 . Chromatographic 
analysis of each of these solutions after adsorption 
showed that 5-HT could not be adsorbed onto alumina from 
aqueous solutions.
Another possible attack of the 5-HT isolation and 
purification focused upon extraction into a non-aqueous 
phase, drying the solvent, and subsequent adsorption onto 
alumina. Although this would conceivcüsly involve more 
time per analysis, it would also be projected to provide 
more selectivity. Elution from the nonaqueous AlgO^
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would be followed by LCEC analysis. Similar isolation 
of 5-HT by alumina column separation had already been 
accomplished using methanol as a solvent-^® Feasibility 
of this adsorption was also partially supported by the 
existent data obtained for phenolic compounds (5-HT is a 
phenolic species) by Higgins and Richards.Using their 
data for phenol, and assuming a nonaqueous volume of 
25 ml containing ca. 1 x lo”  ̂M solute (comparable to the 
contents of a single rat brain), the calculated recovery 
would be approximately 1 0 0 % utilizing heptane as the 
solvent and 50% utilizing ethyl acetate as the solvent 
per gram of AlgOg. Therefore, this method appeared worthy 
of investigation.
A 10~® M serotonin solution was prepared. Two mis
of this solution were added to 40 mis of ethyl acetate in a
separatory funnel and shaken for 20 min. After shaking,
the aqueous layer (lower layer) was removed and the
ethyl acetate layer was dried by shaking with ça. 0.5 g
of euihydrous magnesium sulfate for ça. 10 min. The ethyl
acetate layer was filtered, and 1 0  mis of this filtrate
were shaken with 0.1 g of acid washed alumina,for 30
min. The alumina was then dried at room temperature in a
desiccator under vacuum for 45 to 60 min. The dry alumina
was shêüten for 2 to 5 min with 200 vl 0.1 M HCIO. to elute
— 4
any 5-HT possibly adsorbed. Volumes of 10 to 50 vl of 
this eluent were injected into the LCEC, but no 5-HT was
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detected indicating no adsorption on alumina. This ex­
periment was repeated with nitrobenzene and chloroform 
as solvents, but the results again indicated no adsorption 
of 5-HT on aigOg.
Isolation of NE, DA, and 5-HT by chromatographic 
separation using strong cation exchange resins such as 
Dowex-50, Amberlite CG-120, or Duolite C-25^ was principally 
rejected since that would just be two successive treatments 
with such resins when used in conjunction with the LCEC.
Finally, it was realized that a very highly 
selective method of isolation was simply not obtainable.
Therefore, an investigation of the less selective Shore
38and Olin butanol extraction procedure was undertaken.
This procedure can be briefly described as [1] aqueous 
sample to n-butanol extraction (volume ratios, ca. 1 : 1 0  aqu­
eous to butanol), [2 ] removal of the butanol layer and 
addition of heptane to butanol (volume ratios ca. 1:1.7, 
butanol to heptane) followed by [3] back extraction into 
an acidic aqueous solution. Naturally, this would be 
followed by injection of the final aqueous solution into 
the LCEC apparatus.
38Although the Shore and Olin extraction pro­
cedure was projected to be less selective than, e.g., 
the AlgOg procedures would have been, many factors led 
us to believe it would still form a quite selective 
analytical procedure when combined with the LCEC. These
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factors include: (1 ) the selectivity of the electrochemical
detector at the potential chosen (described in Chapter 1},
(2 ) the utilization of cation exchange resin with a mobile 
phase of pH 5.1 would cause all the neutral and acidic 
metabolites extracted from brain tissue to elute before 
any of these amines (see Chromatographic Interferences, 
this chapter). These factors, added to the ease and 
rapidity of this isolation procedure, made it a method 
definitely worthy of investigation.
However, the Shore and Olin extraction procedure 
was previously utilized only in combination with fluorescence 
as a detection technique. Since we intended to employ it 
with LCEC, an intensive examination of the parameters in­
volved was undertaken.
C. Optimization of the Extraction Procedure for DA/5-HT Analysis
The chromatographic separation of DHBA, DA, and 
5-HT proved to be faster (10 min) than that of NE, DHBA,
DA, and 5-HT (22 min). Therefore, the extraction conditions 
for DHBA, DA, and 5-HT was initially investigated in some 
detail. The reinvestigation of only the appropriate 
parameters for the extended NE/DHBA/DA/5-HT extraction 
were then undertaken.
38In the original method of extraction, the authors 
did not specify the time required for the extraction into 
butanol in the case of standard solutions. However, they
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concluded that the standard solutions should be shaken for 
a period less than that required for the brain tissue to 
minimize losses due to oxidation. Therefore, the following 
study of the time of initial extraction was carried out.
A solution containing 500 vl of the working standard 
(containing DHBA, DA, and 5-HT, see Chapter 2), 1.75 ml 
of the acetate/citrate buffer, and 200 vl of lo”  ̂M DHBA 
was prepared. 50 vl samples of this solution were injected 
into the LCEC to establish the peak heights prior to ex­
traction. Then 1.20 ml of the mixture (pH 5.1) was trans­
ferred to a 30 ml screw-cap vial containing 12.0 ml of 
purified butanol and 1 g NaCl. Separate samples were 
shaken for 5, 20, 40, or 60 minutes. A 10.0 ml pipet 
of the buteuiol layer was transferred to a second vial 
containing 17.0 ml purified heptane and 500 vl of 0.01 M 
HCl. After shaking 5 minutes and allowing 10 minutes for 
the layers to separate, a 50 vl aliquot of the HCl layer 
was injected into LCEC. The percent recovery was established 
by measuring the absolute peak heights, comparing these 
to the same for the non-extracted samples, and correcting 
for dilution as previously described. The results are 
given in Table 3-3. The optimal time appears at 20 minutes. 
This value was chosen for all subsequent investigations 
of standard solutions.
Brain tissue is known to contain large amounts of 
easily oxidized molecules like ascorbic acid. These mole-
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Table 3-3
Percent Recovery of Amines as a Function of Initial Shaking 
Time— Standard Solutions*
Shaking ___________ Recovery, %_____________________
time, min DA 5-HT DHBA
5 47.8+0.9 47.2±1.0 42.0+0.7
20 48.311.9 48.8+1.9 42.8+0.8
40 43.7+0.2 46.910.3 40.910.2
60 40.6±1.5 43.1±3.9 42.812.2
*Purified butanol and heptane used. All results expressed 
as mean of at least six separate determinations l SEM.____
cules act as antioxidants providing protection to the bio­
genic amines. Therefore, in an attempt to minimize losses 
due to oxidation, the addition of ascorbic acid and EDTA 
was studied. 1 0  ul of ascorbic acid ( 1 1 mg/ml) and 1 0 0  yl 
of 0.1 M EDTA were added to the previous solution prior 
to extraction. The results are presented in Table 3-4.
Comparing this traditional ascorbate/EDTA treat­
ment to the results of Table 3-3 points to a better re­
covery for the addition case. In a separate experiment,
50 yl of 1 M NaHSOg replaced the ascorbate as a possible 
antioxidant. However, the NaHSO^ caused a significant 
loss in 5-HT recovery, as previously reported with the 
similar metabisulfite by Welch and Welch. The improved 
recoveries in the case of EDTA and ascorbic acid addition.
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Table 3-4
Percent Recovery of Amines When Extracted in 
Presence of EDTA and Ascorbic Acid^
DA 5-HT DHBA
48.3+0.3 52.9±0.8 50.5+0.8
^Purified butanol and heptane used. Initial shaking time 20 
min. All results expressed as mean of six determinations ± 
SEM._____________________________________________________
however, do not necessarily mean that these species act 
solely as antioxidants. The results may also indicate 
an effect of these additives on the distribution coefficients 
of the amines in the extraction process. Nonetheless, the 
addition was included in all subsequent investigations be­
cause of the improved recoveries.
In fluorometric analyses of biogenic amines, re-
38peatedly washed butanol and heptane or the expensive, 
spectroscopically pure reagents, must be utilized. This 
extreme purity is required to eliminate interferences.
LCEC, on the other hand, should not be sensitive to such 
components. Thus, we examined the effect of using simple 
reagent grade butanol and heptane for extraction instead 
of their tediously purified counterparts. The results 
are given in Ted)le 3-5.
Although the purified reagents do display a signifi­
cantly better recovery for each of the components (P < 0.02, 
n=5) the relatively small difference (6 to 8 % increase)
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Table 3-5
Percent Recovery of Amines for Purified and Unpurified 
Butanol and Heptane Extraction Solvents^
Solvent DA 5-HT DHBA
Non-purified 48.1+0.3 46.6±0.3 41.4±0.3
Purified 52.8±0.8 50.5+0.8 44.8±0.2
Purified butanol and heptêuie prepared by successive washing 
with 1 M HCl, 1 M NaOH, and deionized water according to 
Shore and Olin.Unpurified solvents were reagent grade 
butanol and Baker Analyzed heptane. All results expressed 
as mean + SEM for five sepcurate determinations. P < 0.02 
for each compound._______________________________________
was not deemed enough to justify the time-consuming purifica­
tions. Thus, reagent grade butcmol and heptane were utilized 
for all the following investigations.
Another important factor that determines the sensi­
tivity of the technique used is the volume injected in 
LCEC. Optimization of this volume maximizes the detector 
response. It is desirable that the largest possible volume 
be injected. But, if the volume becomes too large, band 
spreading will destroy the essential separation of components. 
Therefore, we investigated the resolution of adjacent peaks 
for various injected volumes of a mixture composed of 500 
ul of the working standard, 100 ul of 10~^ M DHBA, and 10 
ul of ascorbic acid (solvent front). The results are 
presented in Table 3—6.
The results display adequate (> 1) resolution for
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Table 3 ^
Resolution Between Adjacent Chromatographic Peaks as a 







1 0 1.5 1.5 1.3
25 1.5 1.4 1 . 2
50 1.3 1.3 1 . 2
75 1 . 1 0.87 1 . 1
all pairs of peak except the DHBA/DA combination at 75 ul. 
Figure 3-4 shows the separation obtained for 50 and 75 ul. 
This lack of resolution at larger volumes complicates the 
calculations of results, so 50 ul was chosen as the optimal 
injection volume. However, it is also desirable to have 
this 50 ul contain the largest possible concentration of 
biogenic amines to maximize the LCEC response. A theoretical 
examination of the (1 ) aqueous to butanol and (2 ) butanol/ 
heptane to aqueous extractions shows optimal results will 
be provided if the smallest possible volumes of the initial 
and final aqueous solutions are used.
For the initial aqueous solution a minimum volume 
consists of 100 ul of 0.1 M EDTA, 100 ul of 10~^ M DHBA,
750 ul of acetate/citrate buffer and a 500 ul working 
standard aliquot. Selecting smaller volumes produces












samples which are too viscous to homogenize and manipulate 
for the brain tissues (see Chapter 4). The 0.01 M HCl 
solution in the final extraction was reduced from 500 to 
200 vl. Smaller volumes are physically difficult to handle. 
It should be noted that this decrease in final volume causes 
a definite decrease in the absolute percent recovery; but 
the amount of biogenic amine (nmol or ng) contained in 
the 50 vl LCEC injection is increased.
Using the modifications noted immediately above, 
an investigation of the effect of the pH of the initial 
aqueous solution of standards (measured just prior to 
extraction) was undertaken. The results are given in 
Table 3-7.
As can be seen from Table 3-7, the percent recovery
for each of the amines is fairly constant over the pH
range of 1.1 to 5.2. This result agrees well with the
38report of Shore and Olin. It also shows that if the
standards or samples should become a bit too acidic prior
to their initial extraction, the final result would not
be very adversely affected.
All the previously described investigations were
performed in the absence of tissue. Thus, some examinations
were deemed necessary in presence of brain tissue. Two
parameters we felt would be of importance were the initial
and final times of extraction for brain samples. These
38had been studied by Shore and Olin and showed a maximal
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Table 3-7
Percent Recovery as a Function of Initial Aqueous pH Value^
pH _______________Recovery, %_____________
DA 5-HT DHBA
1 . 1  29.9±1.1 21.4+1.1 23.0+0.6
2.7 35.5+0.3 25.2+0.4 26.2+0.7
3.2 33.2+0.5 24.1+0.6 23.3+0.4
5.2 32.9+0.6 25.4+0.7 24.2+0.3
^All values are reported as mean ± SEM for at least six 
separate determinations._________________________________
recovery when the shaking time for the initial extraction 
into butanol was extended to 1 hour and the time for the 
final extraction was 5 min. We repeated this experiment 
at shaking times of 5, 20, 40 and 60 min. Indeed, our 
results also displayed significantly higher recoveries 
for brain tissue at 60 min. The shaking for the second 
extraction (butanol/heptane to 0.01 M HCl) was also 
examined at 5, 20, 40 and 60 min; but this later time did 
not significantly effect the results. So, 60 min initial 
shaking and 5 min final shaking times were used for all 
tissue samples.
There is no a priori reason to believe that ex­
traction of the biogenic amines is the same in the presence 
of a considerable amount of tissue as in its absence. 
Therefore, a study of recoveries in the presence and absence 
of tissue was carried out as follows. . A brain homogenate
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was prepared by sonicating ten mouse brains in a mixture 
of 1.00 ml of 0.1 M EDTA, 7.50 ml of 0.025 M HCl, and
1.00 ml of deionized water (to replace the usual DHBA).
A 1.00 ml pipet of the homogenate was transferred to each 
of ten separate vials. To five of these homogenate samples 
(Group A) was added a 50 ul aliquot of a solution containing 
2.8xl0“® M DHBA, 4.4xl0“® M DA, and 3.0x10"® M 5-HT. The 
second group of five homogenate samples (Group B) remained 
untreated. Five additional vials (Group C) were then pre­
pared each containing 100 ul of 0.1 M EDTA, 10 ul of 11 mg/ml 
ascorbic acid, 900 ul of the citrate/acetate buffer, and 
50 ul of the same solution of DHBA, DA and 5-HT.
After salt saturation, all fifteen vials were 
subjected to the extraction procedure outlined adx)ve. The 
DHBA, DA, and 5-HT mixture, appropriately diluted, was 
injected to establish peak heights prior to extraction. 
Samples containing only the amines (Group C) were used 
to determine percent recovery in the absence of tissue. 
Percent recovery in the presence of tissue was determined 
by subtracting the samples containing only brain (Group B) 
from those containing both brain and standard addition 
(Group A) and comparing to the data obtained from the 
unextracted samples.
The results are presented in Table 3-8. DHBA and 
DA produced results completely comparable in both cases. 
However, 5-HT yielded significantly lower recovery in the
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presence of brain tissue than in its absence (19.5% com­
pared to 25.2%, P < 0.001, n=8 ). Thus, when using the 
procedure outlined for tissue samples, the final 5-HT 
results must be multiplied by 1.29 (=25.2/19.5) to obtain 
the proper results.
Table 3-8
Percent Recovery in Presence emd Absence of Brain Tissue^ 
_______ Recovery,_%____________________
DA 5-HT DHBA
In presence of 31.0±0.7 19.5±0.7 25.2±0.7
brain tissue
In absence of 31.3±0.8 25.2+0.6 24.3±0.6
brain tissue
^All results in presence of brain tissue represent eight 
separate determinations. All results in absence of tissue 
represent thirteen separate determinations. Results 
expressed as mean ± SEM. Recoveries significantly different 
only for 5-HT (P < 0.001).________________________________
The reason for this difference in percent recovery 
of 5-HT between standards and tissue samples is not clearly 
understood. This anomaly could be due to two possibilities, 
however, which may either be operating separately or to­
gether.
The first of these possibilities is that the brain 
homogenates contain, in addition to ascorbate, other 
substances which protect the amines during the solvent 
extraction procedure. Thus, the brain samples would more
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effectively retard the oxidation of catecholamines and 
indoleamines in the tissue samples as compared to the 
standards. This explcuiation is based on the assumption 
that there are two competing processes involved in maximiz­
ing the recovery. The first process encompasses a slow 
equilibrium between the aqueous and nonaqueous phase (in 
the aqueous to butanol extraction) and is maximized by 
increasing the time of extraction. The second involves 
the oxidation of the extracted compounds and is maximized 
by decreasing the time of extraction.
The second explanation could be that 5-HT in the
brain tissue samples is in fact bound in some way. Thus,
we may be encountering a very slow equilibrium, kinetically
controlled, which first allows the release of serotonin
58from the binding (be it protein or vesicular in nature) 
into the aqueous medium, coupled with the possible slow 
equilibrium between the aqueous and nonaqueous phases 
during extraction. This would explain the long time re­
quired for maximum recovery. Again, oxidation would be 
the limiting factor at very long times, even though it 
might be a relatively minimal process in the short run.
Trying to protect the biogenic amines from oxidation 
during extraction, we decided that shaking at 15®C might 
minimize losses. Thus, we examined the percent recovery 
of the three amines DHBA, DA, and 5-HT with shedcing at 15*C 
and room temperature (21-25*C). Samples were run both in
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the presence euid absence of brain tissue. In all cases, 
the lower shaking temperature produced significantly better 
recoveries. Individual results were relatively some 11-22% 
better for those samples.isolated at 15*C than those isolated 
at room temperature. However, shaking at temperatures <15*C 
did not improve the recovery.
D. Final Assay Procedure for DA and 5-HT Determination
Based on the individual optimizations of both the 
extraction procedure and the LCEC response, we arrived at 
the optimal procedure for the determination of whole mouse 
brains having a typical weight of 450-500 mg. This pro­
cedure is reported here in its entirety for easy reference.
The mice were sacrificed by cervical dislocation.
The brains were removed as rapidly as possible, frozen 
in liquid Ng' stored on dry ice. Each brain was weighed
to the nearest mg and transferred to 30 ml screw-cap vial.
The vials were kept on dry ice during the addition of all 
reagents. The following solutions were added to each vial; 
100 pi of 0.1 M EDTA, 100 pi of 10 M DHBA, and 750 pi of 
0.025 M HCl. While the concentration of DHBA used need not 
be accurately known, the same solution should be used 
throughout a given analysis for both brains and standards.
The cold (but not frozen) mixture was subjected 
to ultrasonic homogenization for ca. 2 0  sec. resulting in 
a homogenate pH of ca. 5.1. Salt saturation was accomplished
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by adding 1 g of NaCl. A 12.0 ml aliquot of n-butanol 
was added to the vial êind the sangles were shaken for 60 
min. A 10-0 ml aliquot of the butanol layer was then re­
moved and placed in a second 30 ml screw-cap vial containing
17.0 ml heptane emd 200 yl of 0.01 M HCl. The second 
bottle was shaken for 5 min and the aqueous layer was 
allowed 10 min to separate. The aqueous layer was then 
transferred by a small disposable pipet to a 3 ml vial.
After removal of the remaining traces of the nonaqueous 
layer, a 50 yl sample of the HCl solution (or a volume 
compatible with the sensitivy of the EC system used) was 
injected into the LCEC apparatus using the optimal chromato­
graphic conditions described previously. If the injection 
was not performed directly after extraction, the final 
HCl solution was stored on dry ice until a few minutes 
before injection. A typical chromatogram of whole mouse 
brain is presented in Figure 3-5.
Working standards (0.500 ml each) were treated 
exactly as the brain samples and were always injected into 
the LCEC on the same day of analysis. The only differences 
for standards were: (1) the initial solution, prior to
homogenization, utilized 750 yl of the acetate/citrate 
buffer instead of the 0.025 M HCl to make the pH comparable 
to that of a brain sample at this stage; (2) 10 yl of the 
ascorbic acid was added to the homogenization mixture to 
mimic brain ascorbic acid levels and to help prevent
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FIGDRE 3-5. A t^ical whole mouse brain determination; 50 pi
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oxidation of the amines; emd, (3) the shaking time for the 
initial extraction into butanol was shortened to 20 min. 
Calculations of all results were performed as described 
in Chapter 2.
E- Optimization of the Extraction Procedure for NE, DA 
and 5-HT Analysis
The optimal extraction procedure as described in 
Section D of this chapter for DA/5-HT was determined to 
be partially unsatisfactory to achieve sufficient resolution 
of NE from the solvent front. This was mainly due to the 
incomplete separation of butanol and butanol/heptane layers 
from the aqueous layers. Such an incomplete separation 
was found to cause some physical carryover of the original 
homogenate into the butanol or butanol/heptane layer and, 
thus, into the final aqueous layer. This caused the 
occurrence of a very large solvent front which overlapped 
with NE. Therefore, solutions had to be centrifuged for 
10 min at 7,900xg after the aqueous to butanol extraction 
and for 1 min at 121xg after the butanol/heptane to aqueous 
extraction.
Since addition of these centrifugation steps con­
stituted a new procedure and since the percent recovery 
for NE was not established in the DA/5-HT analysis, a 
reinvestigation of percent recovery was deemed necessary 
for each component in the present method. The procedure
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used to establish percent recovery is comparable to that 
engployed in Section C of this chapter with some minor 
changes. However, it will be described in detail here 
for clarity.
A brain homogenate was prepared by sonicating ten 
mouse brains in a mixture of 1.00 ml of 0.1 M EDTA, 7.50 ml 
of 0.025 M HCl, and 1.00 ml of 0.01 M HCl (to replace the 
usual DHBA). A 1.00 ml pipet of the homogenate was trans­
ferred to each of ten separate 30 ml centrifuge tubes. To 
five of these was added a 50 pi pipet of a solution con­
taining 2.1x10“® M NE, 2.4x10“® M DHBA, 3.7xl0“® M DA, 
and 3.2x10® M 5-HT. These five tubes will be referred 
to as group A. To another five, known as group B, a 50 ul 
pipet of 0.1 M HCl was added to equalize the volumes. 
Additional centrifuge tubes, constituting group C, were 
prepared with each containing 100 pi of 0.1 M EDTA, 10 pi 
of 11 mg/ml ascorbic acid solution, 900 pi of the citrate/ 
acetate buffer, cUid 50 pi of the same standard solution 
of NE, DHBA, DA, and 5-HT.
Some of the NE, DHBA, DA, and 5-HT samples (group 
C) were injected to establish peak heights prior to ex­
traction. Each mixture, whether or not it contained brain 
tissue, was subjected to ultrasonic homogenization for 
ça. 20 sec, resulting in a "homogenate" pH of ça. 5.1.
Salt saturation was accomplished by adding 1 g of NaCl.
After salt saturation; a 10.5 ml aliquot of butemol
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was added to each tube. The tubes containing brain tissue 
samples were shaken for 60 min, whereas those tubes con­
taining standard solutions were only shaken for 20 min.
The samples were then centrifuged at 7,900xg for 10 min 
at 4°C to completely separate the butanol layer from the 
aqueous layer.
After centrifugation, a 9.6 ml pipet of the butanol 
layer was removed and placed in a second 30 ml vial con­
taining 17.0 ml heptane auad 200 ul of 0.01 M HCl. The 
second tube was shaken for 5 min and centrifuged for 1 min 
at 121xg euid 4*C. After removal of the nonaqueous layer, 
a 20 ul sample, or a volume compatible with the sensitivity 
of detector, was injected into the LCEC apparatus.
Samples which were carried through the extraction 
and contained only amines (group C) were used to determine 
percent recovery in the absence of tissue by comparison 
to the unextracted samples. Percent recovery in the 
presence of tissue was determined by subtracting the peak 
heights of the samples containing only brains (group B) 
from those containing both brain and standard addition 
(group A) and compared to the unextracted results.
The results are presented in Table 3-9. NE, DHBA, 
and DA produced results completely comparable in both the 
presence zind absence of tissue. However, 5-HT again 
yielded significantly lower recovery in the presence of 
brain tissue than in its absence (22.8% as conq)ared to
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Table 3-9
Percent Recovery in Presence êind Absence of Brain Tissue^
____________Recovery, %___________________
NE DHBA DA 5-HT
In presence of 36.1±0.6 36.0±0.9 42.6±1.1 22.8±0.2
brain tissue
In absence of 36.8+0.4 35.8+0.9 41.4±1.0 29.4+0.3
brain tissue
^All results represent eight separate determinations. 
Results expressed as mean < SEM. Recoveries significantly 
different only for 5-HT (P <0.001)._______________________
29.4%, P <0.001, n=8). Thus, we still need to multiply 
the final 5-HT results by 1.29 to obtain the proper results 
for this analysis.
It should be noted that in this particular in­
vestigation, we utilized a 10.5 ml aliquot of butanol in 
the initial extraction and transferred 9.6 ml of this 
solvent to the second vial. This initial volume (10.5 ml) 
was chosen to make the butanol to aqueous ratio 10:1. 
However, we found that in performing the routine analyses 
it was easier to utilize 12.0 ml of the butanol, of which
10.0 ml was then transferred.to the second vial.
There was some concern about the stability of the 
biogenic amines in the final extract (0.01 M HCl), es­
pecially after observing that simply replacing Mallinckrodt 
n-butanol by the Baker Analyzed product caused the peaks 
to be non-gaussian in character and the cunines to be highly
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xinstêüale. Therefore, a study of the stability of this 
extract was deemed necessary in the presence and absence 
of brain tissue after storage at room temperature and on 
dry ice. This study was carried out as follows. In 
separate centrifuge tubes, three brain homogenates were 
prepared by sonicating each of three mouse brains in 100 ul 
of 0.1 M EDTA, 750 ul of 0.025 H HCl and 50 ul of the same 
standard solution as used in the percent recovery study.
Each homogenate was salt saturated by adding 1 g of NaCl.
In the same time, 500 ul samples of the standard was treated 
in the same manner as the individual brains.
After salt saturation, the vials were subjected to 
the extraction procedure outlined above. Immediately after 
extraction, 20 ul of the final extract was injected. A 
second 20 ul injection was then made, after storage either 
at room temperature or on dry ice, at 1 to 24 hours follow­
ing the first. Results for the room temperature samples 
after 1 hr are given in Tables 3-10 and 3-11.
Although there is some decrease in peak ratios 
after leaving the extract at room temperature, this de­
crease is only significant for NE in the absence of brain 
tissue. On the other hand, the similar study performed 
with storage on dry ice showed no decrease in all peak 
ratios after 24 hours. Therefore, in every assay performed 
in our laboratory, the final extracts were always kept on
69
Téüsle 3-10
Study of the Stability of the Final Extract at 
Room Temperature (ça. 23®C) 
in Presence of Brain Tissue^
Peak Ratios
NE/DHBA DA/DHBA 5-HT/DHBA
Immediately after 2.4±0.2 2.3±0.2 0.84±0.02
extraction
1 hr. after 2.3+0.1 2.0+0.1 0.82±0.01
extraction
P—value N.S. H.S. N.S.
^All values reported as mean ±  SEM for six separate deter­
minations. _____ _____ ___  __
Table 3-11
Study of the Stability of the Final Extract at Room
Temperature (ca. 23®C) in Absence of Brain Tissue^
_______________Peak ratios________________
NE/DHBA DA/DHBA 5-HT/DHBA
Immediately 1.54+0.02 1.38+0.02 0.51+0.02
after
extraction
1 hr. after 1.44+0.02 1.32+0.03 0.50+0.02
extraction
P-value P <0.01 N.S. N.S.
^All values are reported as meaui ± SEM for six separate 
determinations. _________ ______________________
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dry ice until 3 min before injection. Additionally, 
storage of the final extracts on dry ice never exceeded 
24 hours.
F. Final Assay Procedure for the NE, DA, and 5-HT Deter­
mination
This assay was performed exactly in the same way 
as the DA/5-HT assay described previously in Section D 
of this chapter. The only differences are (1) the analysis 
should be accomplished in Teflon centrifuge tubes (see 
Chapter 2), (2) the solutions should be centrifuged after 
the aqueous to butanol extraction at 7,900xg and 4*C,
(3) the solutions should be centrifuged at 121xg and 4*C 
after the heptane/butanol to aqueous extraction, and (4) the 
working standards utilized should contain HE, DA, and 5-HT 
in concentrations comparable to the brain (see Chapter 2).
Injections should be made into the LCEC system 
described for this assay in Section A of this chapter. A 
typical whole mouse brain chromatogram for the NE/DA/5-HT 
analysis is shown in Figure 3-6.
G. Modification of the NE/DA/5-HT Assay for the Analysis 
of Biogenic Amines in Brain Parts
Appropriate modifications were required to com­
pensate for the differing amine concentrations of individual 
brain parts. However, in applying these modifications:
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initial extraction was always maintained at ça. 1:10;
(2) the ratio of butanol to heptane was always maintained 
at ca. 1:1.75; (3) the volume of 0.01 M HCl solution in 
the final extraction was always 200 vl; (4) the volume 
of standards (in ul) / run at the same time as ""the samples, 
was comparable to the sample weight (in mg); (5) the times 
of the first and second extractions were maintained at 
60 and 5 min, respectively, for the samples, and 20 and 
5 min for the standards; and (6) the concentration of 
DHBA, the internal standard, was appropriately reduced 
so that its peak height became comparable to those of 
the biogenic amines in the part analyzed. It should also 
be noted that the volumes of both the working standard 
solution and the DHBA solution used were chosen to be 
large enough (50 yl or more) such that reproducibility 
was easily obtainable.
Considering the remarks immediately noted above, 
the following assay procedure was deemed optimal for the 
determination of cerebellum, hippocampus, medulla-pons, 
midbrain and diencephalon. These brain parts had an 
average wt. of 25-50 mg.
The weighed brain part was transferred to a Teflon 
centrifuge tube. The following solutions were added to 
the tube: 10 y1 of 0.1 M EDTA, 50 yl of 10“® M DHBA, and
100 yl of 0.025 M HCl. The mixture was subjected to ultra­
sonic homogenization for ca. 10 sec. The homogenate was
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salt saturated by adding 0.05 g NaCl. A 2.2 ml aliquot 
of butanol was added to the tube and the samples were 
shaken for 60 min. The tube was then centrifuged at 7,900xg 
at 4°C. A 1.5 ml portion of the butanol layer was then re­
moved and placed in a second Teflon centrifuge tube con­
taining 2.5 ml heptane and 200 ul of 0.01 M HCl. The 
second tube was shaken for 5 min and then centrifuged at 
121xg and 4®C. The aqueous layer was transferred by a 
disposable pipet to a 2 ml vial. After removing the re­
maining traces of the butanol/heptane layer, a volume of 
the HCl solution compatible with the detector sensitivity 
was injected into the LCEC apparatus. The solution contents 
and volumes for these brain pairts and their standards, 
as well as the two succeeding parts, are summarized in 
Tables 3-12 to 3-14.
Working standards for these brain parts (50 ul) were 
treated exactly as the brain tissue samples. The only dif­
ferences were: (1) the initial solution prior to homogeniza­
tion utilized 100 ul of the acetate/citrate buffer instead 
of the 0.025 M HCl; (2) 5 ul of the ascorbic acid solution 
(2 mg/ml) was added to the homogenization mixture; and
(3) the shaking time for extraction into butanol was 
shortened to 20 min.
For the analysis of striatum (average wt. ca. 25 
mg), 100 ul of 4x10 ® M DHBA was utilized to result in a 
peak height comparable to that of DA. This necessitated
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Table 3-12
Solutions Added Prior to Homogenization for Brain Parts
Analyses^





0.025 M HCl 
(samples) or buffer^ 
(standards)
Cerebellum 10 1 50 100
Hippocampus 10 1 50 100
Medulla-pons 10 1 50 100
Midbrain 10 1 50 100
Diencephalon 10 1 50 150
Striatum 10 4 100 350
Cortex 50 4 100 350
The EDTA and DHBA solutions were acced to both the tissue 
scunples and standards.
^Citrate/acetate buffer, pH=5.1.
^5 vl of ascorbic acid (2 mg/ml) was added to each standard 




Materials Dsed for Extraction in Brain Parts Analyses*
Brain part Initial volume Volume of butanol Volume of 
of butanol obtained after heptane
added, ml initial extraction added for
ml final ex­
traction, ml
Cerebellum 2.2 1.5 2.5
Hippocampus 2.2 1.5 2.5
Medulla-pons 2.2 1.5 2.5
Midbrain 2.2 1.5 2.5
Diencephalon 2.2 1.5 2.5
Striatum 3.2 2.5 4.2
Cortex 7.0 5.0 9.0
*In the second extraction. the butanol obtained after the
first extraction was combined with the heptane and the 
amines were extracted into 200 vl of 0.01 M HCl. Numbers 
given refer to both the tissue samples and standards.____
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Table 3-14
Working Standards Used in Brain Parts Analyses of HE, DA,
and 5-HT®
Brain part Volume employed Concentrations
in analysis, pi NE(ng/ml) DA(ng/ml) 5-HT(ng/ml)
Cerebellum 50 432 824 712
Hippocampus 50 432 824 712
Medulla-pons 50 432 824 712
Midbrain 50 432 824 712
Diencephalon 50 432 824 712
Striatum 50 335 1665 624
Cortex 200 432 824 712
®A11 standards 
M HCl.
were prepared in a deaerated solution of 0.01
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adding 150 yl of 0.025 M HCl to the tissue sample or 150 yl 
of the citrate/acetate buffer to the standard solutions. 
Consequently, the volume of the butanol aliquot added was 
3.2 ml, of which 2.5 ml was then pipetted into a second 
tube containing 4.2 ml heptane and 200 yl of 0.01 M HCl. 
Other procedural details for striatum remained essentially 
the same as those noted immediately above.
In the case of cortex (average wt ca. 200 mg), the 
volume of standards employed was 200 yl. Also, 100 yl of 
4x10  ̂M DHBA was utilized for both standards and samples. 
350 yl of 0.025 M HCl was added to the tissue samples, 
and 350 yl of pH 5.1 acetate/citrate buffer to the standard 
solution. Therefore, the volume of butanol aliquot was 
chosen to be 7.00 ml of which 5.00 ml was pipetted into 
the second tube containing 200 yl of 0.01 M HCl and 9.00 ml 
of heptane.
The same assay procedures as those outlined above 
are directly applicable to the determinations of only DA 
and 5-HT. However, for the DA/5-HT determinations, one 
need not include the centrifugation steps after each ex­
traction and the LCEC conditions used should obviously 
be the more rapid DA/5-HT conditions (not the longer 
NE/DA/5-HT ones used here).
CHAPTER IV
DETERMINATION OP DOPAMINE AND SEROTONIN IN MOUSE 
BRAIN TISSUE APPLICATIONS
A. Whole Mouse Brain
The assay developed for the analysis of dopamine 
and serotonin, as described in Section D, Chapter 3, was 
applied to whole mouse brain analysis to demonstrate the 
general applicability of the procedure.
The result for a total of 40 samples is given in 
Table 4-1, along with the reported values of other in­
vestigators. As can be readily seen, the levels for both 
DA and 5-HT are well within the range of previously re­
ported determinations. Yet, the present method yields 
both values simultaneously; no sample splitting, pooling, 
derivatization, or enzymatic reactions are required. The 
assay is quite simple and easy to perform.
Methods of Homogenization
During the developnent of this assay procedure, 
Alliger®^ reported that long exposure of biological samples 




Whole House Brain Dopamine and Serotonin Concentrations^
Investigators Technique of DA,ng/g±SEM 5-HT,ng/g±SEM 
Detection (n) (n)
Present Report LCEC 973±16(40) 805±12(40)
Fleming et al.^* Fluorescence 770±6(13) 550+10(10)
Wiegand & Perry®®Fluorescence 870±46(12) 820±12(3)
Welch & Welch^® Fluorescence 700-900(1000) 600-800(100)
Smith®^ Fluorescence 820±31(5) 660il3(5)
Agrawal et al.®^ Fluorescence 1330±98(6) 410±16(6)
Weintraub et alf^ GCMS 800±30(5) 670±40(5)
^All results reported as mean + SEM._____________________
indole nucleus of tryptophan. Since 5-HT also contains 
an indole moiety, we compared ultrasonic homogenization 
to that performed with a ground glass apparatus. As pre­
sented in Table 4-2, there was no significant effect on 
the results.
Routine Application
With the present single column setup, it has been 
possible to run as many as 30 samples during a normal eight- 
hour day. This required that the tissue samples were al­
ready weighed at the start of the day. However, it also 
included sufficient time to clean all appropriate glass­
ware while the chromatography was being run. When 
sacrificing and tissue removal were included, 20 samples
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Table 4-2
Effect of Homogenization Method on Whole Mouse Brain 
Determination of Dopamine and Serotonin^
Method of homogenization DA, ng/g 5-HT, ng/g
Ultrasonic 1023+60 837+44
Ground glass 985±30 810±23
^All values reported as mean ± SEM for five separate deter­
minations. There is no significant difference between 
methods of homogenization for either DA or 5-HT.___________
could be easily accommodated in the same time period. The 
number of samples per day, however, may be increased
45significantly by utilizing the dual parallel LCEC apparatus 
previously discussed.
Column Stcibility
In our laboratory, we utilized the same column of 
Zioax sex for more than one year without any noticeable 
change in resolution. However, to extend the column life, 
we would recommend that, if the column is not to be used 
for a few weeks, it should be washed with deionized water 
and 0.01 M HCl. This will maintain the column at a pH 
of 2 and inhibit bacterial growth.
B. Mouse Brain Parts
The assay for the analysis of biogenic amines in 
mouse brain parts has been described in Section G, Chapter 
3. This assay was applied to the cuialysis of brain parts
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dissected from decapitated and from microwaved mice primarily 
to display the sensitivity of this method.
Rapid post mortem changes in the levels of a variety 
of importeuit neurochemicals have been recently demonstrated. 
Unless the enzymes involved in the metabolism of these 
compounds are rapidly inactivated in situ, extraction 
and subsequent analysis of these con^unds results in 
erroneous values. Rapid freezing techniques and the more 
rapid microwave irradiation have adequately demonstrated 
this for acetylcholine,®^'®® the cyclic nucleotides,®^ 
y-aminobutyric acid,®® and some high energy phosphate 
molecules.®®
In the analysis of NE, DA, and 5-HT in whole mouse 
brains, the rapid enzymatic inactivation by microwave 
irradiation has previously been found to be unnecessary.®^
The present research was performed to see the effect of 
sacrificing by microwave exposure on the regional concen­
trations of these biogenic amines.
Sacrificing of the mice was accomplished by either
(1) decapitation or (2) exposure to 6 kw of focused micro­
wave irradiation at 2450 MHz for 250 msec. All animals 
were subjected to the following sequence: (1) sacrifice,
(2) rapid brain removal and dissection into seven major 
parts,®® (3) freezing and storage of the brain parts on 
dry ice until analysis, and (4) measurement of the biogenic 
amine levels in each part.
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Results and Discussion
The results of the analyses for DA and 5-HT are 
presented in Table 4-3. Individual values represent the 
combination of two separate sets of data, each showing 
essentially the same results. As can be seen, the DA values 
in only the striatum are significantly larger for the micro- 
waved animals than for the decapitated ones. 5-HT values 
are significantly higher for microwaved animals in five 
of the seven brain regions examined. These results were 
very disconcerting in view of the fact that whole brain 
biogenic amine values had previously®^ been shown to be 
unaffected by microwave vs. decapitation methods of 
sacrifice. Thus, we sought more extensive confirmation 
of this data.
An analysis of NE and DA, utilizing the alumina 
isolation procedure with LCEC,®® completely verified the 
results for DA shown in Table 4-3 (i.e., microwaved and 
decapitated DA values only significantly different in the 
striatum). This NE/DA procedure also displayed no 
significant differences for NE values when microwaved and 
decapitated samples from all the parts were examined.
Still remaining somewhat skeptical of the discovery of 
a DA and, possibly, a 5-HT "pool" which was so rapidly 
degraded after death, we fortified our results by two 
additional routes. First, we repeated the DA/5-HT analysis 
for striatum some five additional times, each verifying
Table 4-3
Dopamine and Serotonin Concentrations of Mouse Brain Parts^









Cerebellum 9 52 19±2 23+2 12524 293215^
Hippocampus 11 26 65±8 94+22 520219 747228^
Medulla-pons 12 41 77±12 67214 1023246 1117249
Midbrain 11 30 95+11 119212 966252 1231294^
Diencephalon 10 41 199±21 225220 889290 1050280
Striatum 10 22 4627+127 77902210^  606286 817215^
Cortex 11 171 696+58 618239 626225 729225®
®All values expressed as mean ± SEM. Decapitated and micro- 
waved results are not significantly different (P >0.05) 
except where noted.
^Number of individual samples determined. In striatum, for 
example, there were 10 analyses each performed on the decapi­
tated and microwaved animals.
°5-HT results corrected for percent recovery in presence of 
tissue by multiplying the final result obtained by 1.29.
^Significantly higher (P <0.001) results for microwaved 
animals.
^Significantly higher (P <0.01) results for microwaved 
animals.
^Significantly higher (P <0.05) results for microwaved 
animals.
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the original. Secondly, we examined microwaved and de­
capitated mouse striatum by use of the GCMS method of 
Koslow et al.^® Again, the original results for DA were 
confirmed.
In order to microwave animals, however, a quite 
rigid immobilization of the animals is required. For pro­
perly focusing the beam of radiation, the animal is 
typically placed in a modified 50 ml plastic syringe with 
the head exposed. The body and most of the head is then 
immobilized by "packing" the animal in this apparatus.
The decapitated animals are typically not confined in 
this manner. But, this immobilization stress is certainly 
capable, by itself, of causing changes in the levels of 
biogenic amines. Thus, we examined the effect of immobilizing 
both the decapitated and microwaved animals prior to sacrifice. 
As shown in Table 4-4, the results are still significantly 
higher for microwaved animals (P <0.001 for DA and 5-HT 
in striatum). Hence, immobilization stress is clearly not 
the source of the differences we observe.
At this stage, we were totally convinced that the 
microwave/decapitation differences were quite real and not 
simply due to analytical methodology or immobilization.
But another possibility also existed, i.e., that the micro­
wave irradiation could be somehow "releasing" some tightly 
bound form of DA or 5-HT. This tightly bound form could 
also be present in decapitated samples but was simply not
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Table 4 ^
Dopamine and Serotonin Concentrations in Mouse Striatum 
After Immobilization^
DA (ng/g) ̂  5-HT (ng/g)
decapitated microwaved decapitated microwaved
8034+394 11134+262 673±29 927+35
^All values expressed as mean + SEM, n=6. Both decapitated 
and microwaved animals were similarly immobilized just 
prior to sacrificing.
<0.001 for microwaved vs. decapitated samples in case of both DA and 5-HT._____________________________________
measured due to its inaccessibility via the procedures 
chosen for analysis. Thus, we needed to examine a possible 
microwave artifact. The best method for testing this hypo­
thetical artifact was determined to be through direct 
comparison of the striata of a normally microwaved group 
to a group that was first decapitated and then (5 minutes 
after decapitation) submitted to the same microwave treat­
ment. In this test, the normally microwaved animals (DA= 
9350+970 ng/g, n=9) were significantly greater (P <0.01) 
than those submitted to decapitation plus microwave treat­
ment (DA=7750±130 ng/g, n=4). Additionally, a group of 
normally decapitated animals (DA=7720±610, n=12) were 
significantly different (P <0.01) from the normally micro- 
waved group and not significantly different from the 
decapitated plus microwaved group. Thus, no microwave 
artifact can be operational in providing the results we
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have obtained.
But what does the microwave treatment provide that 
is not present in decapitation? Surely, the most obvious 
characteristic of microwaving as a method of sacrificing 
animals is the phenomenal temperature rise it effects in 
the brain (from 37®C to 80-100®C in 200 msec). This 
temperature excursion virtually destroys all enzymatic 
activity through dénaturation of the proteins. Knowledge 
concerning which enzyme is involved in the post mortem 
degradation of these amines could give us insight into 
the location of these highly labile "pools" that disappear 
between death itself (as measured in microwaved samples) 
and the time required for isolating the striatum (a time 
only relevant to the decapitated samples where the enzymes 
are still intact after death). As such, we decided to 
examine both DA levels and enzymatic activities for enzymes 
involved in DA metabolism as a function of time of microwave 
irradiation. Hopefully, the increase in DA seen between 
0 msec (decapitated) and 200 msec of irradiation would 
closely match the loss of activity of one of the metabolic 
enzymes, thus allowing a correlation to be made. As 
presented in Table 4-5 and Figure 4-1, the DA appears to 
quite readily increase between 100 and 200 msec of micro­
wave irradiation. The only enzyme examined to date, DOPA 
decarboxylase (DDC), does not show a good correlation 
with these DA results. In fact, some detectable amounts
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Table 4-5
Concentrations of Dopamine in Striatum as a Function of
Microwave Irradiation Time
Microwave
time (msec) n DA (ng/g)





All values expressed as mean ± SEM.
of DDC activity are already lost at only 70 msec of micro­
wave treatment. We hope to obtain similar data for tyrosine 
hydroxylase, monoamine oxidase, êind catechol-O-methyl 
transferase in the near future. However, until we do obtain 
such data, it is impossible to speculate upon the cellular 
localization of these "pools". Likewise, we hope to be 
able to more precisely pin down the location of the 5-HT 
pools via examination of the appropriate metabolic enzymes.
The present results do seem to display an apparently 
anomalous effect. When comparing microwaved to decapitated 
animals, NE shows no differences in all regions examined,
DA is significantly different only in the striatum, and
5-HT is different in all but two of the seven areas. This 




FIGURE 4-1. Concentrations of dopamine in striatum as
a function of microwave irridiation time.
I
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however, makes the differences, where they do appear, even 
more credible. Since these biogenic amines, by other 
techniques, typically yield half-lives on the order of 
hours, DA and 5-HT (in the regions showing significant 
differences) must also have "pools" or compartments with 
much shorter half-lives, i.e., minutes. Or, in these 
selected regions, these transmitters must be experiencing 
storage in multiple compartments ̂ ̂ 0 » ̂ 1,7 2 multiple
compartmentation is a highly controversial issue, it has 
previously gained support for striatal DA by the long term 
post mortem studies in rat brain^^ and the 5-HT work of 
Grahame-Smith.^^ These multiple pools, it should be noted, 
may also exist in the regions showing no significant dif­
ferences (microwave vs. decapitated) in the present study; 
but, they may be small enough that the instrumental and 
animal-to-animal variations simply camouflage their existence.
Hopefully, as mentioned above, future studies in 
this area will allow us to find which particular metabolic 
enzymes are involved in the rapid post mortem degradation 
of biogenic amines seen after decapitation. Since the 
predominate locations of each of these metabolic enzymes 
has been well established, we should then be able to more 
precisely locate these rapid turnover "pools" and, there­
fore, be able to more accurately assess their function.
CHAPTER V
DETERMINATION OF NOREPINEPHRINE, DOPAMINE, AND 
SEROTONIN IN MOOSE BRAIN 
TISSUE APPLICATIONS
A. Whole Mouse Brains
The assay developed for the analysis of norepinephrine, 
dopamine, and serotonin is described in Section F, Chapter 
3. This assay was also applied to the analysis of whole 
mouse brains to demonstrate its general applicability.
The result of 48 separate whole brain determinations 
is given in Table 5-1. Some literature values obtained by 
other techniques are given for comparison in Table 5-2.
The mean values for the present method agree very 
well with the literature values. Yet, this method is the 
first to quantitate all three of these biogenic amines 
simultaneously in the same tissue sample without splitting, 
pooling, derivatization or enzymatic reactions.
B. Daily Rhythms in Norepinephrine, Dopamine, and Serotonin 
Concentration in Mouse Brain










Whole Mouse Brain Analysis-Literature Values^
NE,ng/g±SEM DA,ng/g±SEM 5-HT,ng/g±SEM Detection,
(n) (n) (n) Reference Technique
350-450 700-900 600-800 26 F
(1000) (1000) (1000)
450±15 770+6 550+10 59 F
(11) (13) (10)
360+16 870+45 820+12 60 F
(10) (12) (3)
470+30 800±30 670±40 63 GCMS
(5) (5) (5)
350+30 850±20 550±20 63 F
(6) (6) (6)
^All results presented as mean ± SEM for the reported number
of samples.
^F- Fluorescence 
GCMS- Gas chromatography mass spectroscopy.
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circadian rhythms of NE, DA, and 5-HT in mouse trains is 
very poor. A change in these levels as a function of the 
time of day is very important to many psychological ex­
periments presently being performed by other workers.
49Halberg et , in their study of 5-HT concentrations 
in mouse brains, are the only investigators to have re­
ported results in this area. Therefore, we decided to 
investigate the diurnal variations in the concentrations 
of the biogenic amines in mouse brain.
Male Sprague-Dawley mice weighing 20 to 30 g were 
housed under constant environmental conditions for at least 
7 days before the experiment, as previously described in 
Chapter 2. The lighting cycle consisted of lights on from 
0700 to 1900 hr. and lights off from 1900 to 0700 hr.
Groups of five mice were sacrificed by cervical dislocation 
every 4 hr. beginning at 0400 hr. Additionally, five mice 
were sacrificed 1 hr. before and after turning the lights 
on and 1 hr. before and after turning the lights off. The 
brains were removed as rapidly as possible, frozen in 
liquid Ng, stored on dry ice for 24 hr., and then assayed 
for NE, DA, and 5-HT. The results are shown in Table 5-3 
and Figure 5-1.
From the results, it appears that all three biogenic 
amines exhibit a fairly reasonable diurnal variation with 
a single maximum and a single minimum at sometime during 
the 24 hr. period. Thus, NE displays its greatest value
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Table 5-3
Norepinephrine, Dopamine, and Serotonin Concentration in 
Mouse Brain at Certain Times of Day^



















- - - Lights turned off - - - 
368±39 720±83 550+58
463+11 799+35 614+27
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FIGURE 5-1. Daily rhythms in NE, DA, and 5-HT concentrations 
in mouse brain.
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at 2400 hr. and its least value at 1200 hr. DA has a 
definitive maximum at 0400 hr. and an apparent minimum at 
1600 hr. Serotonin, on the other hcmd exhibits a little 
less variation, with a maximum at 0400 hr. and a broad 
minimum between 0800 and 2000 hr.
The ratio of the maximal to minimal results for 
each amine was: NE, 1.48; DA, 1.38; and 5-HT, 1.25. And, 
the maximum value was significantly larger than the minimum 
value in all three cases (P <0.01). This clearly shows 
that diurnal variations must be considered in any experi­
mental results when the controls and treated animals are 
not sacrificed at the same time of day.
C. Comparison of the Effects of 6-Aminodopamine and
g-Methyl-6-aminodopamine on the Central Nervous System 
A major advance in knowledge concerning the function­
ing of both adrenergic and serotonergic systems has come 
from the use of neurochemically selective destroying agents. 
However, the selectivity of presently available agents is 
by no means absolute. Thus, 100% destruction of noradre­
nergic, dopaminergic, or serotonergic pathways has not been 
attained. Also, the destruction of any one of these systems 
is frequently accompeinied by a concurrent disruption of 
another system.
6-Aminodopamine (6-ADA) is one of the compounds that 
has shown destruction of ^mpathetic n e u r o n s . I t  was
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first shown to deplete NE stores in mouse brain by Blank 
77et al. Its selectivity towards NE neurons was also shown
to be somewhat higher than 6-hydroxydopamine (6-OHDA) by 
78Oke et However, the destructive effect of 6-ADA on
NE neurons is still not complete.
79Porter and coworkers, have demonstrated that 6- 
aminodopamine, 6-hydroxydopamine, and their a-methyl 
derivatives are all capable of producing a long-lasting 
depletion of catecholamines from the hearts of mice as 
well as from certain peripheral tissues of dogs. Evidence 
has also been presented to suggest that a-methylation of 
6-OHDA increases its potency towards NE neurons.®® There­
fore, we decided to study the effect of a-methyl-6-amino­
dopamine (o-Me-6-ADA) as compared to 6-ADA on NE, DA, 
and 5-HT in mouse brains utilizing the LCEC analysis.
6-ADA and o-Me-6-ADA were kindly prepared by Mr.
OlPat Cohenour via modifications of the method of Stone. 
Solutions of both were prepared, immediately before in­
jection, in thoroughly deaerated isotonic saline containing 
1 mg/ml ascorbic acid to minimize air oxidation. Samples 
were introduced by direct intracranial injection into 
male ARS-HA/ICR mice weighing 20-30 g under light ether 
anesthesia. A microsyringe was used with an arresting 
stop which permitted a penetration depth of 3 mm. Mice 
were treated in groups of 24, including 8 controls and 16 
expérimentais. Injections, spaced apart at 24 hr. intervals.
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contained 50 ug of the neurotoxin in a volume of 5 wl. 
Controls received equivalent injections of the isotonic 
saline with ascorbic acid. 24 hours after the last in­
jection, the mice were killed by cervical dislocation.
The brains were removed as rapidly as possible and assayed 
for NE, DA, and 5-HT as described before. The results 
are given in Table 5-4.
As shown in Table 5-4, a-methylation of 6-ADA 
significantly increased NE depletion (P <0-02) while the 
effect on DA remained comparable to that of 6-ADA. This 
indicates higher potency of a-methylation in destroying 
NE neurons. But, this study also indicates that both 
6-ADA and a-Me-6-ADA cause significant depletion (P <0.05) 
of 5-HT. This result is potentially very disruptive to 
many existent behavior studies performed with 6-amino- 
dopamine. Concurrent destruction of 5-HT in the use of
6-ADA or a-Me-6-ADA means that behavioral results obtained 
may also be experiencing an effect due to the loss of 
this transmitter; consideration of only the NE and DA 
depletions in such investigations, thus, may no longer 
be entirely adequate.
The present results also indicate that a-Me-6-ADA 
may be more toxic than 6-ADA, as shown by the number of 
survivals (5 out of 8 as compared to 7 out of 8 for 6-ADA). 
This data, while not being definitive at the present time, 
does point to the use of lower dosages in future investiga-
Table 5-4
Depletion of NE, DA, and 5-HT in Whole Mouse Brain by 6-ADA and a-Me-6-ADA^
Compound Dosage . NE DA 5-HT
Schedule Total n ng/g % Control ng/g % Control ng/g % Control
a-Me-6-ADA 2x50 gg 100 ug 5 133±13 29 723+40 76 480+48 79
6-ADA 2x50 gg 100 gg 7 196±17 43 788+35 83 490±43 80





tions of o-Me-6-ADA to minimize these toxic effects.
D. Simultaneous Estimation of Norepinephrine, Dopamine, 
and Serotonin in Seven Discrete Areas of Mouse Brain
Obtaining data on discrete areas of brain rather 
than from the whole brain has already been shown to be of 
considerable importance. ' The biogenic amine levels 
of the different brain areas have displayed a wide variation 
upon drug t r e a t m e n t . W h i l e  a particular amine may 
greatly decrease in one area after treatment, the same 
amine may show an increase or no change at all if examined 
in another area. In addition, since it is widely accepted 
that there is considerable functional interaction between 
the putative neurotransmitters, concurrent estimation of 
two or more neurotransmitter levels in the same sample of 
brain tissue should find increasing application. There­
fore, we applied the assay described in Section G, Chapter 
3 for the determination of NE, DA, and 5-HT to the smaller 
mouse brain parts to demonstrate its sensitivity and 
usefulness.
The results obtained comprise the first report 
of data for NE, DA, and 5-HT in these discrete areas of 
mouse brain. The method is intended to be widely applicable 
to drug screening and behavioral studies. It eliminates 
the necessity for pooling, which provides information about 
groups rather than individuals. Additionally, it avoids
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the larger costs and longer analysis time associated 
with pooling.
Results and Discussion
The results of these brain parts analyses are 
given in Table 5-5. Although we could not find any 
references to NE, DA, and 5-HT in these regions of mouse 
brain, the results do agree fairly well with those reported 
for rat brain parts.
The method was also used to determine 3-MT in 
striatum (456±74 ng/g, n=6). Figure 5-2 shows a typical 
chromatogram for such a striatum determination. The 
sensitivity of the method, however, is probably best shown 
in Figure 5-3 which represents a typical chromatogram for 
cerebellum. -ais is a small part (57 mg) with an extremely 
low concentra:.on of DA (28 ng/g). Yet all the biogenic 
amines can sti .1 be measured and quantitated.
In conclusion, the procedure described for the 
simultaneous determination of NE, DA, and 5-HT (and even
3-MT, if desired) in mouse brain tissue by LCEC is rapid, 
selective, inexpensive, and comparable or better in 
sensitivity to the more expensive GCMS and radiochemical 
techniques. It has been used routinely for the analysis 
of ca. 15 individual brain paurt samples per day.
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Table 5-5
Concentrations of NE, DA, and 5-HT in Regions of Mouse Brain 
Brain region Average weight NE(ng/g) DA (ng/g) 5-HT(ng/g)
(mg)
Cerebellum 57 296+14 28±4 103+8
Medulla-pons 43 535+40 59±7 812±54
Midbrain 36 616±39 126±9 1015+49
Diencephalon 44 625+41 200+12 974+76
Hippocampus 33 254+46 84+28 453+93
Striatum 23 153+13 4777+380 579+25
Cortex 198 256±34 673+67 630±47
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S-HT8 0  pg 
DA
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FIGURE 5-3. A typical chromatogram of mouse cerebellum, 
30 vl injection.
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Catechol-O-me thy Itrcinsf erase 
Dihydroxybenzylamine 
Dihydroxyphenylalanine 
DOPA decarboxylase 
Dopamine 
Epinephrine
5-Hydroxyindoleacetic acid
5-Hydroxytryptamine (serotonin)
5-Hydroxytryptophan
Metanephrine
3-Methoxytyramine
a-Methyl-6-aminodopamine
a-Methyldopamine
Monamine oxidase
Norepinephrine
Normetanephrine
Tryptophan hydroxylase
Abbreviation
SAM
6-ADA
COMT
DEBA
DOPA
DDC
DA
E
5-HIAA
5-HT
5-HTP
M
3-MT
c-Me—6—ADA
o—MeDA
MAO
NE
NMN
TPH
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